 S1702  
 Page 1 
 Version Date 7/10/19  
  
PRIVILEGED COMMUNICATION  
FOR INVESTIGATIONAL USE ONLY 
  
SWOG 
TITLE  
A PHASE II STUDY OF ISATUXIMAB (SAR650984) (NSC -795145) FOR PATIENTS WITH 
PREVIOUSLY TREATED A L AMYL OIDOSIS  
 
NCT# 03499808  
 
STUDY CHAIRS : AGENTS : 
 
Terri Parker , M.D. (Medical Oncology)  SWOG -Held IND Agents : 
Yale School of Medicine  Isatuximab (SAR650984) (NSC#795145)  
[ADDRESS_110094]   (IND-138083)  
P.O. Box [ADDRESS_110095] [ZIP_CODE]  
Phone: 203/737- 7059   
FAX: 203/737- 3401  
E-mail: [EMAIL_1969]   BIOSTATISTICIANS : 
 
Vaishali Sanchorawala, M.D. (Medical Oncology)  Antje Hoering, Ph.D. (Biostatistics)  
[LOCATION_011] Medical Center  Kari Chansky, M.S. (Biostatistics)  
[ADDRESS_110096]  
Phone:  617/638- 8265  Seattle, WA [ZIP_CODE]- 1468  
FAX:  617/638- 6518  Phone:  206/652- 2267  
E-mail:  [EMAIL_1970]   FAX:  206/652- 4612  
 E-mail:  [EMAIL_1971]   
ALLIANCE  CHAMPI[INVESTIGATOR_45372] : E-mail:  [EMAIL_1972]   
 
Heather J. Landau, M.D.   
Memorial Sloan Kettering Cancer Center  
[ADDRESS_110097]  
[LOCATION_001], NY [ZIP_CODE]  
Phone: 212/639- 8808  
E-mail: [EMAIL_1973]   
 
ECOG-ACRIN CHAMPI[INVESTIGATOR_45372] : 
 Erica  Campagnaro, M.D.  
E-mail:  [EMAIL_1974]
  
PARTICIPANTS  
 
U.S. Only 
 
ALLIANCE /Alliance for Clinical Trials in Oncology  
ECOG-ACRIN /ECOG -ACRIN Cancer Research Group  
NRG /NRG Oncology  
SWOG /SWOG  
 
 
  
  
 S1702  
 Page 2 
 Version Date 7/10/19  
  
TABLE OF CONTENTS  
 
TITLE  ......................................................................................................................................................... 1  
PARTICIPANTS  ............................................................................................................................................ 1  
TABLE OF CONTENTS  ............................................................................................................................... 2  
CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT [CONTACT_99935] ....................... [ADDRESS_110098] of Care  ................................................................................................................. 6  
2.3  Isatuximab ........................................................................................................................................ 6  
2.4  TED [ZIP_CODE] Phase I Study  ............................................................................................................... 7  
2.5  Hypot hesis  ....................................................................................................................................... 8  
2.6 Response Criteria  ............................................................................................................................ 8  
2.7 Inclusion of Women and Minorities  .................................................................................................. 9  
3.0 DRUG INFORMATION .................................................................................................................... 9  
3.1 Isatuximab (SAR650984) (NSC #795145, IND -138083)  ................................................................. 9  
4.0 STAGING CRITERIA  ..................................................................................................................... 16 
5.0 ELIGIBILITY CRITERIA  ................................................................................................................ 16 
5.1 Disease Related Criteria  ................................................................................................................ 16 
5.2 Prior/Concurrent Therapy Criteria  .................................................................................................. 17 
5.3 Clinical/Laboratory Criteria  ............................................................................................................. 18 
5.4 Specimen Submission Criteria  ....................................................................................................... 20 
5.5 Regulatory Criteria  ......................................................................................................................... 20 
6.0 STRATIFICATION FACTO RS ....................................................................................................... 20 
7.0 TREATMENT PLAN  ...................................................................................................................... 21 
7.1 General Treatment Instructions  ..................................................................................................... 21 
7.2 Pre-Medication  ............................................................................................................................... 22 
7.3 Treatment  ....................................................................................................................................... 23 
7.4 Organ Evaluation Guidelines  ......................................................................................................... 23 
7.5 Criteria for Removal from Protocol Treatment  ............................................................................... 24 
7.6 Discontinuation of Treatment  ......................................................................................................... 24 
7.7 Follow-Up Period  ................................................................................................ ............................ 24 
8.0 TOXICITIES TO BE MON ITORED AND DOSE MODI FICATIONS  .............................................. 25 
8.1 NCI Common Terminology Criteria for Adverse Events  ................................................................ 25 
8.2 Supportive Care  ............................................................................................................................. 25 
8.3 Dose Delays  ................................................................................................................................... 25 
8.4 White Blood Cell Growth Factors  ................................................................................................... 26 
8.5 Guidelines for the Management of Infusion Reactions (IRs)  ......................................................... 26 
8.6 Dose Delay Contacts  ..................................................................................................................... 27 
8.7 Adverse Event Reporting  ............................................................................................................... 27 
9.0 STUDY CALENDAR  ...................................................................................................................... 28 
10.0  CRITERIA FOR EVALUAT ION AND ENDPOINT ANA LYSIS ..................................................... 33 
10.1  Measurable disease  ....................................................................................................................... 33 
10.2  Hematologic Response and Progression  ....................................................................................... 33 
10.3  Organ Response () ......................................................................................................................... 33 
10.4  Criteria for Organ Progression  ....................................................................................................... 35 
10.5  Time to Hematologic Response  ..................................................................................................... 36 
10.6  Overall Survival  .............................................................................................................................. 36 
10.7  Progression- Free Survival .............................................................................................................. 36 
10.8  Performance Status  ....................................................................................................................... 36 
11.0  STATISTICAL CONSIDER ATIONS  .............................................................................................. 36 
11.1  Two-Stage Design  .......................................................................................................................... 36 
11.2  Sample size and Power Justification  ............................................................................................. 37 
 S1702  
 Page 3 
 Version Date 7/10/19  
  
11.3  Analysis of  Primary Endpoint  ......................................................................................................... 37 
11.4  Analysis of Secondary and Other Endpoints  ................................................................................. 37 
11.5  Safety Analysis  ............................................................................................................................... 38 
12.0  DISCIPLINE REVIEW  .................................................................................................................... 38 
13.0  REGISTRATION GUIDELI NES ..................................................................................................... 39 
13.1  Regis tration Timing  ........................................................................................................................ 39 
13.2  Investigator/Site Registration ......................................................................................................... 39 
13.3  OPEN Registration Requirements  ................................................................................................. 42 
13.4  Registration Procedures ................................................................................................................. 43 
13.5  Exceptions to SWOG registration policies will not be permitted.  ................................................... 44 
14.0  DATA SUBMISSION SCHEDULE  ................................................................................................ 44 
14.1  Data Submission Requirement  ...................................................................................................... 44  
14.2  Master Forms  ................................................................................................................................. 44 
14.3  Data Submission Procedures  ........................................................................................................ 44 
14.4  Data Submission Overview and Timepoints  .................................................................................. 45 
15.0  SPECIAL INSTRUCTIONS ............................................................................................................ 46 
15.1  Translational Medicine and Banking ( OPTIONAL ) ........................................................................ 46 
16.0  ETHICAL AND REGULATORY CONSIDERATIONS  ................................................................... 50 
16.1  Adverse Event Reporting Requirements ........................................................................................ 50 
17.0  BIBLIOGRAPHY  ............................................................................................................................ 56 
18.0  APPENDIX  ..................................................................................................................................... 58 
18.1  [LOCATION_001] Heart Association Classifications  .................................................................................. 59 
18.2  Neuropathy Impairment Scale – Lower Limbs  ............................................................................... [ADDRESS_110099] Pregnancy Reporting Consent  ................................................................................. 62 
18.5  [COMPANY_011] Exposure During Pregnancy (EDP) Form  .......................................................................... [ADDRESS_110100]  ................................................................................................ 69 
18.7  Measuring Orthostatic Blood Pressure  .......................................................................................... 70 
 
  
 S1702  
 Page 4 
 Version Date 7/10/19  
  
CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS  AND CONTACT [CONTACT_99936]:  
 For patient enrollments:  For study data submission:  
Regulatory documentation must be 
submitted to the CTSU via the 
Regulatory Submission Portal:  
 (Sign in at www.ctsu.org, and 
select the Regulatory Submission 
sub-tab under the Regulatory tab.)  
 Institutions with patients waiting that are unable to use the Portal should alert the CTSU Regulatory 
Office immediately at 1- 866-651-
[ADDRESS_110101] the CTSU Regulatory Help 
Desk at 1- [PHONE_102] for 
regulatory assistance.  Please refer to the patient 
enrollment section of the 
protocol for instructions on using the Oncology Patient Enrollment Network (OPEN) 
which  can be accessed at  
 
https://www.ctsu.org/OPEN_SYSTEM/  
 or  
 https://OPEN.ctsu.org.  
 Contact [CONTACT_99937] -related 
questions at : 
 [EMAIL_013]
. 
  Data collection for this study will 
be done exclusively through Medidata Rave.  Please see the data submission section of the protocol for further instructions.  
 
Do not  submit study data or 
forms to CTSU Data Operations. Do not  copy the CTSU on data 
submissions.  
 
Other Tools and Reports : 
Institutions participating through 
the CTSU continue to have 
access to other tools and reports 
available on the SWOG Workbench. Access this by 
[CONTACT_99938] -IAM 
userid and password at t he 
following url:  
 
https://crab.crab.org/TXWB/ctsul
ogon.aspx   
 
The most current version of the study protocol and all supporting documents  must be downloaded 
from the protocol -specific Web page of the CTSU Member Web site located at https://www.ctsu.org.   
Access to the CTSU members’ website is managed through the Cancer Therapy and Evaluation 
Program - Identity and Access Management (CTEP -IAM) registration system and requires user log on 
with CTEP -IAM username [CONTACT_2383].    
For patient eligibility or data submission questions contact [CONTACT_99939]:  
 
206/652- 2267  
[EMAIL_1975]    
 
For treatment or toxicity related questions contact [CONTACT_99940]:   
[CONTACT_99994]  at 203/737- 7059  or [EMAIL_1969]  or  
[CONTACT_99995] at 617/638- 8265 or [EMAIL_1970]     
 
For non-clinical questions (i.e. unrelated to patient eligibility, treatment, or clinical data 
submission) contact [CONTACT_56113] e- mail:  
 
CTSU General Information Line – [PHONE_031], or [EMAIL_013] .   
 
All calls and correspondence will be triaged to the appropriate CTSU re presentative.  
The CTSU Website is located at  https://www.ctsu.org . 
 S1702  
 Page 5 
 Version Date 7/10/19  
  
1.0 OBJECTIVES  
 
1.1 Primary Objectiv e 
 
To assess the efficacy as measured by [CONTACT_99941] 
(partial response or better) of  isatuximab in relapsed/ refractory systemic light chain (AL) 
amyloidosis.  
 
1.2 Secondary Objectives 
 
a. To evaluate toxicities in the treatment of relapsed/ refractory AL amyloidosis with  
isatuximab.  
 
b. To evaluate time to hematologic response.  
 
c. To evaluate duration of response.  
 
d. To evaluate progression- free survival (PFS).  
 
e. To evaluate overall survival (OS).  
 
1.3 Other Objectives  
 
a. To evaluate efficacy of isatuximab in relapsed/ refractory immunoglobulin amyloid light chain (AL) amyloidosis  as measured by [CONTACT_99942] 
(cardiac, renal, GI, liver, soft tissue, nerve) , in the subset of patients that can be 
evaluated for organ response.  
 
b. To evaluate time to organ response in the subset of patients that can be evaluated 
for organ response. 
 
 
2.0 BACKGROUND  
 
2.1  Study Population  
 Systemic  light chain (AL) amyloidosis is a monoclonal plasma cell disease in which 
misfolded light chains spontaneously aggregate into soluble oligomers and insoluble fibrils.  Extracellular fibril deposition in different organs leads to organ dysfunction and symptoms. Historically, survival after a diagnosis of AL amyloidosis has been short, particularly in 
patients with advanced cardiac involvement (with a median survival of 3- 6 months). (1)  
Current therapy for AL amyloidosis generally targets the small light ch ain-producing 
monoclonal plasma cell population in the bone marrow. Therapeutic regimens have been adapted from myeloma therapy.  
 
Approximately 1/3 of AL patients are eligible for high- dose melphalan and autologous stem 
cell transplantation (ASCT), with t he remaining patients generally being treated with 
alkylator and/or bortezomib -based regimens. The outcomes of [ADDRESS_110102] from July 1994 to December 2008 revealed the median event -free survival 
(EFS) and overall survival (OS) were 2.[ADDRESS_110103], 43% achieved a complete response (CR) and 
78% of them experienced an organ response. For CR subjects, median EFS and OS were 
8.3 and 13.2 years, respectively. Among the 195 subjects who did not obtain CR, 52% 
reached an organ response, and the median EFS and OS were 2 and 5.9 years, respectively. (2)  Cardiac involvement at diagnosis and response to therapy are the two 
main determinants of survival in both ASCT and non-ASCT patients.  
  
 S1702  
 Page 6 
 Version Date 7/10/[ADDRESS_110104] proven to 
be beneficial in AL amyloidosis as well. To this end, both the immunomodulatory drugs (IMiDs; thalidomide and lenalidomide) and the proteasome inhibitor bortezomib have been 
studied as treatments for AL amyloidosis with variable degrees of efficacy and toxicity often 
requiring dose reduction. There are no currently FDA -approved pharmacologic agents for 
relapsed AL amyloidosis.  
 The immunomodulatory drugs (IMiDs), thalidomide and lenalidomide, in combination with dexamethasone are associated with overall hematologic response rates of 40- 50% for 
relapsed AL, with some organ responses seen, though toxicities are significant and dose reductions are often needed.  (3) Outcomes of AL patients with relapsed and refractory 
disease previously treated with bortezomib, lenalidomide and autologous stem cell 
transplant (40- 80%) with pomalidomide and dexamethasone resulted in overall 
hematologic response rates of 48- 51% in two studies. Median time to hematologic 
response was 1.9 months (range, 0.9- 11.3) and median duration of response 19 months. 
Organ improvement was documented in 18% overall (15% cardiac, 25% renal).  Median and 3 year PFS were 14 months and 17% respectively. Median and 3- year OS were 28 
months and 41%. (4,5) Bortezomib also has significant activity in the newly diagnosed and 
relapsed setting. (6,7) Median time to response with combination cyclophosphamide; 
bortezomib and dexamethasone (CyBorD) is 2 months. (8) 
 
Despi[INVESTIGATOR_99897], there remains a desperate need 
for other treatment options that will be available to patients when they relapse or are intolerant to standard medications. The development of newer classes of drugs with less 
toxicity at standard doses and novel mechanisms of action for AL are certainly warranted, 
however, they should be tested cautiously and as single agents to establish preliminary 
data on efficacy and safety before considered in combination with other agents. Setting an 
estimated benchmark response rate for this novel drug for relapsed AL cannot  be based 
on responses to other active agents such as the IMiDs or bortezomib as described above, 
as the class of drug (monoclonal antibody) has never been given to AL patient s. Thus, the 
goal of this single arm open label study is to establish if there is  a preliminary efficacy signal 
without serious toxicity as this is the first study using a CD38 monoclonal antibody in AL. A reasonable expectation for hematologic response may be based on the efficacy seen as 
a single agent in relapsed multiple myeloma (ORR 27%).  
 
2.3  Isatuximab  
Isatuximab (SAR) is an IgG1ĸ monoclonal antibody (mAb) that binds with high affinity to a 
unique epi[INVESTIGATOR_83825]38. It is a targeted immunotherapy that attacks tumor cells that 
overexpress CD38, a transmembrane glycoprotein, in a variety of hematological 
malignancies including plasma cell malignancies. Isatuximb induces lysis of CD38-expressing tumor cells, including malignant plasma cells by a wide spectrum of 
mechanisms including complement -dependent cytotoxicity (CDC) and antibo dy-dependent 
cell-mediated cytotoxicity (ADCC). The most common adverse reactions  seen are  infusion 
reactions that can be mitigated  and managed with corticosteroids and antihistamines, both 
as prophylaxis and treatment .  
 
Isatuximab has been shown to be efficacious and well tolerated in relapsed and refractory 
multiple myeloma patients when used as a single agent as well as in various combinations 
with other agents . 
  
 S1702  
 Page 7 
 Version Date 7/10/19  
  
 
2.4  TED [ZIP_CODE] Phase I Study  
 
Final results are available for the Phase I study TED10893.  Preliminary clinical activity 
results as of the cutoff dates are provided for Phase 2, Stage 1 of Study TED10893.  
 In the Phase I study (TED10893), [ADDRESS_110105] been treated with isatuximab at doses up to 10 mg/kg QW or 20 mg/kg QW. Six patients (5 with MM, 1 with NHL) were treated in the accelerated escalation cohort. Thirty -nine patients (35 with MM, 2 with NHL, and 2 with chronic lymphocytic leukemia 
[CLL]) were treated in the basic escalation cohorts. Nineteen and 18 patients with MM (standard or high risk) and high risk MM were treated in dose expansion cohorts 1 and 2, respectively. In an additional  cohort, 7 patients with MM were treated with isatuximab, 20 
mg/kg QW.  
 For all 89 treated patients, the median number of cycles administered was 5 (range, 1:56), 
the median duration of exposure was 10.1 weeks (range, 2:116), and the median relative 
dose intensity was 98.48%.  
Eighty -one patients discontinued treatment  (69, due to disease progression (PD), 4 due to 
adverse events (AEs), 8 for reason recorded as “other,” Consent withdrawal [8 patients]) and 8 remain on treatment. The median time on treatment was 10.1 weeks (range, 2 to 16 weeks).  
 In 84 patients with MM, the median age was 64 years (range, 40 to 81 years). The median time from diagnosis to first isatuximab dosing was 5.8 years (range, 1.2 to 22.8 years). The 
median number of prior lines of therapi[INVESTIGATOR_26615] 5.0 (range, 1 to 13). Prior therapy included 
lenalidomide (94.0%), pomalidomide (40.5%), bortezomib (98.8%), and carfilzomib (42.9%).  
 Among the 89 patients enrolled, and across all the treatment cohorts, Grade ≥3 treatment -
emergent AEs (TEAEs) were reported in 53.9% of patients, serious TEAEs in 39.3%, 
TEAEs with fatal outcome in 2.2%, TEAEs leading to treatment discontinuation in 5.6%, 
and dose limiting toxicities (DLTs) in 2.2%.  
 
The most common were infusion- associated reaction (IARs) (in 49.4% of the patients, 
overall, including 2 patients with IARs to pre medication treatment and not related to 
isatuximab; Grade 3- 4 in 2.2%), fatigue (in 37.1% of the patients, overall; Grade 3- 4 in 
3.4%), nausea (in 32.6% of the patients, overall; Grade 3- 4, none), anemia (in 28.1% of 
the patients, overall; Grade 3- 4 in 16.9%), upper respi[INVESTIGATOR_1092] (in 22.5% of the 
patients, overall; Grade 3- 4, none), cough (in 22.5% of the patients, overall; Grade 3- 4, 
none), back pain (in 20.2% of the patients,  overall; Grade 3- 4 in 3.4%), and diarrhea (in 
20.2% of the patients, overall; Grade 3- 4, none).
 
 
Overall response rate (≥partial response (PR)) using the European Society for Blood and 
Marrow Transplantation criteria among the 84 treated MM patients was 20.2% (1 CR, 15 
PRs), all responses PR or better are confirmed with 2nd assessment. Clinical benefit rate (≥ minimal response (MR)) was 26.2% and best response was stable disease in 42.9% of 
the treated MM patients. The MR or better occurred at all dose lev els ≥1 mg/kg. In patients 
treated at doses ≥10 mg/kg in the dose escalation and expansion cohorts (n=63), ORR was 23.8% (15 of 63 patients), and the CBR was 30.2% (19 of 63 patients). In patients 
treated at 10 mg/kg Q2W in the high- risk cohort (n=18), ORR was 16.7% (3 of 18 patients) 
and CBR was 27.8% (5 of 18 patients).  
 In the Phase II, Stage 1 study TED10893,  97 patients were treated in Phase 2, Stage 1 of 
Study TED10893: 23 patients at 3 mg/kg Q2W, 24 patients at 10 mg/kg Q2W, 25 patients 
at 10 mg/kg Q2W/Q4W, and 25 patients at 20 mg/kg QW/Q2W. As of the cut -off date (29 
 S1702  
 Page 8 
 Version Date 7/10/19  
  
February 2016), 85 patients discontinued treatment, 73 due to PD, 7 due to  
 
AEs, and 5 due to reason recorded as “other” (non- IMWG confirmed PD [2 patients], 
Consent withdrawal [2 patients], lack of response [1 patient]). Twelve patients remain on 
treatment.  
 
Patients received 1 of 4 different doses or schedules of administration. The median age 
was 62.0 years (range, 38 to 85 years). The median time from diagnosis to first isatuximab 
dosing was 5.85 years (range, 1.2 to 24.1 years). Patients were generally heavily 
pretreated and were exposed to most of the available anti- MM treatment. All patients 
received at least 1 immunomodulatory drug (IMiD) (ie, lenalidomide, pomalidomide) or proteas ome inhibitors (ie, bortezomib, carfilzomib, ixazomib).  
 
For all 97 treated patients, the median number of cycles administered was 3 (range, 1:17), 
the median duration of exposure was 13.1 weeks (range, 4:69), and the median relative dose intensity was 98.85%.  
 The ORR showed a dose response effect between the 3 mg/kg Q2W (ORR<10%) and doses of 10 mg/kg or higher (ORR ≥20% in all arms). At doses of 10 mg/kg or higher, the 
response rate ranged from 20% to 29% without a meaningful dose response between the 
10 mg/kg and the 20 mg/kg arms.  
 
The median duration of responses were: 12.9 months (3.7– 14.8) at 10 mg/kg Q2W; 9.2 
months (3.7– 13.8) at 10 mg/kg Q2W/Q4W; and 8.75 months (4.6– 9.9) at 20 mg/kg 
QW/Q2W.  
 
The response rates are consistent cross all sub- groups. In patients treated at doses ≥10 
mg/kg, ORR was ≥20% in all sub- groups, including patients with high- risk cytogenetics 
(38% [8/21]).  
 The median PFS was: 3.7 months (1.84–10.15) across all dose levels . The median OS for 
10 mg/kg Q2W group was 18.628 (9.9220 to NC) months,  and has not been reached in 
the 10 mg/kg Q2W/Q4W and 20 mg/kg QW/Q2W arms . 
 
Among the 97 patients enrolled, and across all the treatment cohorts, Grade ≥3 TEAEs 
were reported in 63.9% of patients, serious TEAEs in 43.3%, TEAEs with fatal outcome in 10.3% (and 5 because of disease progression), and TEAEs leading to treatment 
discontinuation in 8.2% of the patients (2 due to infusion- related reactions, 1 due to Grade 
3 thrombocytopenia, and 5 patients  unrelated to toxicity ). The most common TEAEs were 
nausea (35.1%; Grade 3- 4, none), fatigue (30.9%; Grade 3- 4, none), cough (28.9%; Grade 
3-4 in 1%), and dyspnea (26.8%; Grade 3- 4 in 3.1%).  
 
Infusion- associated reactions were reported in 49 of 97 patients  (50.5%) patients across 
all dose levels. The severity of the IARs was Grade 3 or higher in 3 (3.1%) patients. The symptoms of IARs with a severity of Grade 3- 4 consisted of anaphylactic reaction, 
hypertension, dyspnea, bronchospasm (in 1 patient each).  
 
2.[ADDRESS_110106] that the 
efficacy and tolerability will be similar to that of daratumumab as seen in AL amyloidosis . 
(9,10,11) 
 
2.[ADDRESS_110107] historically been based on the 
consensus opi[INVESTIGATOR_99898] (ISA,2005); 
 S1702  
 Page 9 
 Version Date 7/10/19  
  
cardiac and hematologic response was subsequently updated at the XIIth ISA (2012) and 
more recently the renal response criteria have been revised by [CONTACT_99943]  (2014) which 
are now widely accepted. We will use these criteria for evaluating hematologic and organ 
response on this trial (See Sectio n 10.0) . (12,13,14) 
 2.7 Inclusion of Women and Minorities  
 
This study was designed to include women and minorities,  but was not designed to 
measure differences of intervention effects.  The anticipated accrual in the ethnicity/race and sex categories is shown in the table below.   
 
DOMESTIC  PLANNED ENROLLMENT REPORT  
Racial Categories  Ethnic Categories  Total Not Hispanic or Latino  Hispanic or Latino  
Female Male Female  Male   
American Indian/ Alaska 
Native  0 1 0 0 1 
Asian  1 0 0 0 1 
Native Hawaiian or Other 
Pacific Islander  0 1 0 0 1 
Black or African American  3 3 0 0 6 
White  10 13 2 2 27 
More Than One Race  1 2 0 0 3 
Total 15 20 2 2 39 
 
  
3.0 DRUG INFORMATION 
 
Investigator Brochures   
 
For information regarding Investigator Brochures, please refer to SWOG Policy 15.  
 For this study, isatuximab is investigational and is being provided under an IND held by [CONTACT_99944].  For INDs filed by [CONTACT_99944], the protocol serves as the Investigator Brochure for the performance of the protocol.  In such instances submission of the protocol to the IRB should suffice for providing the IRB with information about the drug.  However, in cases where the IRB insists on having the 
official Investigator Brochure from the company, further information may be requested by [CONTACT_99945] 210/614- 8808. 
 Diphenhydramine, methylprednisolone, ranitidine and acetaminophen are commercially available and should therefore be purchased by a third party.  These drugs will not be supplied by [CONTACT_99946].
 
 
3.1 Isatuximab (SAR650984) (NSC # 795145, IND -138083 ) 
 
a. PHARMACOLOGY  
 
Mechanism of Action:  
Isatuximab is an immunoglobulin G1 monoclonal antibody that selectively binds to 
the human cell surface antigen molecule CD38 expressed in a number of hematological malignancies from B- lymphocyte, T -lymphocyte, and myeloid origin. 
The agent works through antibody -dependent cellular -mediated cytotoxicity, 
 S1702  
 Page 10  
 Version Date 7/10/19  
  
complement -dependent cytotoxicity, antibody dependent cellular phagocytosis , 
and induction of apoptosis.  
 
b. PHARMACOKINETICS  
 
1. Absorption : Exposure increased more than proportionally with the dose 
from 0.03 to 20 mg/kg. Some accumulation was observed following 10 or 
20 mg/kg administered with qw or q2w schedule. Achievement of steady 
state has not been formally evaluated yet. Additionally, four doses of 20 
mg/kg QW showed that total clearance (sum of nonlinear and linear clearances) approached linear clearance (indicating target saturation) 
after which the 20 mg Q2W schedule appeared to maintain the total 
clearance close to the linear clearance.  
 
Isatuximab has a low clearance to those of non- specific endogenous IgG 
associated with a half -life of 18 days and the volume of distribution of 
central compartment (Vp) approached the blood volume. Because 
isatuximab is an antibody, it is expected to be eliminated by [CONTACT_99947].  
 
 
2. Distribution : The PK of isatuximab appeared to be nonlinear in the dose 
range investigated in studies.  More precisely, after the first administration, the exposure (AUC1week, AUC2weeks, or AUClast) appeared to increase 
more than proportionally with the dose up to 10 mg/kg, while no major deviation to the dose proportionality could be observed between 10 mg/kg 
and 20 mg/kg.  This nonlinearity suggests the presence of target -mediated 
drug disposition with isatuximab.  
 
3. Metabolism : No available data; being evaluated. 
 
4. Elimination : Some accumulation was observed following 10 or 20 mg/kg 
administered with every -week  or every -2-week  schedule. Achievement of 
steady state has not been formally evaluated yet.  
 
c. ADVERSE EFFECTS   
 
1. Adverse Effects : 
 
Adverse Events with Possible  
Relationship to “Isatuximab”  
Likely (> 20%)  Less Likely (4 – ≤ 
20%) Rare but Serious (≤ 
3%) 
BLOOD AND LYMPHATIC SYSTEM DISORDERS  
Anemia  Febrile neutropenia   
Leukopenia  Hyperviscosity 
syndrome   
Thrombocytopenia    
Lymphopenia    
Neutropenia    
CARDIAC DISORDERS  
 Atrial fibrillation  Cardiopulmonary 
failure  
 Acute coronary 
syndrome  Stress 
cardiomyopathy  
 S1702  
 Page 11  
 Version Date 7/10/19  
  
Adverse Events with Possible  
Relationship to “Isatuximab”  
Likely (> 20%)  Less Likely (4 – ≤ 
20%) Rare but Serious (≤ 
3%) 
   
EYE DISORDERS  
 Eye pain   
 Photophobia   
 Visual impairment   
GASTROINTESTINAL DISORDERS  
Nausea  Constipation  Small intestinal 
obstruction  
Diarrhea  Abdominal pain  Gastrointestinal 
amyloidosis  
Vomiting   Gastrointestinal 
hemorrhage  
  Ileus  
  Intussusception  
  Obstruction gastric  
  Tongue edema  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  
Fatigue  Performance 
decreased  Device malfunction  
Pyrexia  Non-Cardiac Chest 
Pain Disease progression  
Chills  Asthenia  Gait disturbance  
 Pain  
 Face edema   
HEPATOBILIARY DISORDERS  
AST increased  Hyperbilirubinemia   
ALT increased    
Alkaline phosphatase 
increased    
IMMUNE SYSTEM DISORDERS  
   Anaphylactic 
reaction  
INFECTIONS AND INFESTATIONS  
Upper respi[INVESTIGATOR_99899]  
 S1702  
 Page 12  
 Version Date 7/10/19  
  
Adverse Events with Possible  
Relationship to “Isatuximab”  
Likely (> 20%)  Less Likely (4 – ≤ 
20%) Rare but Serious (≤ 
3%) 
  Pneumococcal 
bacteremia  
  Pneumonia 
respi[INVESTIGATOR_99900], POISONING AND PROCEDURAL COMPLICATIONS  
Infusion related 
reaction  Fall  
 Hip fracture   
 Humerus fracture   
 Joint injury   
 Procedural 
hemorrhage   
 Traumatic fracture   
INVESTIGATIONS  
Blood bilirubin 
increased    
Blood creatinine 
increased    
METABOLISM AND NUTRITION DISORDERS  
Hypercalcemia  Decreased appetite  Pathological fracture  
 Hypercalcemia   
 Tumor lysis 
syndrome   
MUSCULOSKELETAL AND CONNECTIVE TISSURE DISORDERS  
Back pain  Bone pain   
 Fracture pain   
 Musculoskeletal 
chest pain   
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (incl ude 
cysts and polyps)  
  Basal cell carcinoma  
  Malignant 
melanoma  
  Myelodysplastic 
syndrome  
  Squamous cell 
carcinoma of the 
oral cavity  
 
NERVOUS SYSTEM DISORDERS  
Headache  Dizziness  Cerebral 
hemorrhage  
 S1702  
 Page 13  
 Version Date 7/10/19  
  
Adverse Events with Possible  
Relationship to “Isatuximab”  
Likely (> 20%)  Less Likely (4 – ≤ 
20%) Rare but Serious (≤ 
3%) 
 Seizure  Transient ischemic  
attack  
  Spi[INVESTIGATOR_99901], THORACIC AND MEDIASTINAL DISORDERS  
Cough  Respi[INVESTIGATOR_99902]  
 
2. Pregnancy and Lactation: Reproductive toxicology studies have not yet 
been performed.  
 
Drug Interactions : No drug -interactions has been observed between 
isatuximab and lenalidomide. 
 
d. DOSING & ADMINISTRATION  
 
See Section 7.0  Treatment Plan  
 
Isatuximab should be administered via a peristaltic pump using an administration set that is polyethylene (PE) or polyvinyl chloride (PVC) DEHP free or polyvinyl 
chloride (PVC) with DEHP with 0. 2 micron in-line filter that is polyether sulfone 
(PES) or Nylon.  Isatuximab initial infusion rate should not exceed 175 mg of 
isatuximab per hour.  In the absence of infusion related reactions (IAR), after 1 
hour of infusion, the infusion rate can be increased by 50 mg/hour increments 
every 30 minutes, to a maximum of 400 mg/hour.  Subsequent infusions should be 
initiated at 175 mg/hour.  In the absence of IARS, the rate may  be increased by 
100 mg/hour every 30 minutes, to a maximum of 400 mg/hour.   Patients who do 
not experience an IAR during the first [ADDRESS_110108] their need for subsequent premedication reconsidered at the Investigator’s discretion in 
consultation with the Study C hairs  to avoid unnecessary sedation.   
 S1702  
 Page 14  
 Version Date 7/10/19  
  
 
e. HOW SUPPLIED  
 
1. Isatuximab vials will be provided by [CONTACT_99948] : 
 
[COMPANY_011] US Services Inc.  
[ADDRESS_110109]  
Malvern, PA [ZIP_CODE]  
[LOCATION_003] 
 
2. Isatuximab C1P2F2 (cell 1, process 2, formulation 2) drug product is presented as a concentrate for solution for infusion in vials containing 20 mg/mL (500 mg/25 mL) isatuximab in 20 mM histidine, 10% (w/v) sucrose, 
0.02% (w/v) polysorbate 80, pH 6.0 buffer . 
 
3. Isatuximab is supplied for parenteral administration as a sterile, nonpyrogenic, injectable, 20 mg/mL concentrate for solution for infusion, 
essentially free of particulates , and is packaged in [ADDRESS_110110] 
be discarded.  
 
f. STORAGE, PREPARATION & STABILITY 
 
1. Isatuximab will be stored between +2 and +8°C and protected from light 
upon receipt. Shelf -life of isatuximab is currently 24 months. Refer to the 
S1702 training slides  for temperature excursion information.   
 
2. Isatuximab concentrate for solution for infusion will be diluted in an infusion bag with 0.9% sodium chloride s olution or 5% dextrose solution to achieve 
the appropriate drug concentration for infusion.  
 Infusion via a central line is preferred if available. In case of patients with 
local intolerance after peripheral IV infusion, decision to use central line is 
left to investigator decision. The final infusion volume corresponding to the dose of isatuximab will be administered by [CONTACT_99949].  
 
3. Dilution should be performed in an aseptic condition per local guidelines. Select appropriate diluent bag volume of NaCl 0.9% and/or Dextrose 5% 
solutions that are polyolefin (PO), polyethylene (PE) or polypropylene (PP), or polyvinyl chloride (PVC) with DEHP to ensure diluted product 
concentration is between 0.8 and 5.3 mg/mL. Doses ≥ 3,[ADDRESS_110111] be 
diluted in Dextrose 5% solution. Bag sizes between 250 mL and 1,000 mL 
can be used to prepare the infusion solutions ; bags of 2 50 mL, 500 mL, or 
1,000 mL are recommended for this study . Add appropriate amount of 
isatuximab into the bag and gently homogenize by [CONTACT_99950]. 
Follow local procedures for priming of tubing and filter and for use of a 
secondary line. Prepared solutions for infusion are stable at room 
temperature for 16 hours.  
 
4. Prior to dosing, each patient's dose will be individually prepared by [CONTACT_99951], patient number, and treatment description. The patient’s weight should be measured prior to 
each cycle; however dose should only be changed if the patient has > 10% 
change in weight.  
 S1702  
 Page 15  
 Version Date 7/10/[ADDRESS_110112] volume of concentrated solution needed for the 
dose, apply the following equation:  
 
Vdose (mL) = [Dose (mg/kg) x Body weight (kg)]/20 (mg/mL)  
 Example: for a 70 kg patient dosed at 20 mg/kg:  
Vdose is (20 x 70)/20 =  70 mL of Isatuximab 
 
6. To calculate the number of vials needed for the dose follow these steps:  
 
1.   Patient dose (vials) = Vdose (mL)/ [ADDRESS_110113] upper unit  
 
Example: for a 70 kg patient dosed at 20 mg/kg the calculated patient dose 
is 2.8 vials, then 3 vials should be used to obtain the volume of 
concentrated solution.  
 
g. DRUG ORDERING & ACCOUNTABILITY  
 
1. Drug ordering: Isatuximab may be ordered by [CONTACT_99952] S1702 Drug Order and Acknowledgment of Receipt Form per the 
instructions on the form. The form can be found on the protocol abstract page of the SWOG website (
www.swog.org ) or on the protocol abstract 
page  of the CTSU website ( www.ctsu.org ). 
 
2. Drug Handling and Accountability  
 
a. Drug Accountability: The investigator, or a responsible party designated by [CONTACT_093], must maintain a careful record of 
the receipt, disposition, and return or disposal of all drugs received 
from the supplier using the NCI Drug Accountability Record Form (DARF) available at http://ctep.cancer.gov.  
 b. Electronic logs are allowed as long as a print version of the log process is the exact same appearance as the current NCI DARF.  
 
c. Sites must also document drug receipt (including temperature excursion information) and the acknowledgment must be returned 
to [COMPANY_011] per the instructions on th e S1702  Drug Order and 
Acknowledgment of Receipt Form.  The form can be found on the 
protocol abstract page of the SWOG website ( www.swog.org ) or 
on the protocol abstract page of the CTSU website (
www.ctsu.org ). 
 
3. Drug Disposition Instruction  
 
a. Used vials and expi[INVESTIGATOR_99903] a timely 
manner.  Unused vials should be destroyed on site per institution SOP and  documented accordingly on the DARF upon study 
closure and the last enrolled patient has completed treatment.  
 
b. Drug expi[INVESTIGATOR_1516]: (If packaging does not have expi[INVESTIGATOR_320], 
check with insert from company when available. If packaging has 
expi[INVESTIGATOR_320], indicate drug expi[INVESTIGATOR_99904] 
 S1702  
 Page 16  
 Version Date 7/10/19  
  
Manufacturer and Lot # and use the drug lots with shorter 
expi[INVESTIGATOR_99905]) . 
 
4. Contact [CONTACT_99953][INVESTIGATOR_99906]-US-Shipment -[EMAIL_1976] . 
  4.[ADDRESS_110114]® (see Section 14.0
).  Any potential eligibility issues should be addressed to the 
Data Operations Center in Seattle at 206/652- 2267 or [EMAIL_1975]  prior to 
registration. NCI policy does not allow for waiver of any eligibility criterion 
http://ctep.cancer.gov/protocolDevelopment/policies_deviations.htm . 
 
In calculating days of tests and measurements, the day a test or measurement is done is 
considered Day 0.  Therefore, if a test is done on a Monday, the Monday [ADDRESS_110115] relapsed or refractory primary systemic AL Amyloidosis, 
histologically -confirmed by [CONTACT_99954], OR characteristic appearance by [CONTACT_99955][INVESTIGATOR_007] (mass spectrometry -based pr oteomic 
analysis or immunofluorescence) .  If there is question regarding diagnosis, consult 
Study C hairs prior to submission via e- mail to  [EMAIL_1969]
 and 
[EMAIL_1970] . Pathology report must be submitted as indicated 
in Section 14.4a . 
 
b. Patient must have measurable disease as defined in Section 10.1  within 28 days 
prior to registration. Serum β2 microglobulin, Serum Quantitative Immunoglobulins 
(IgG, IgA, and IgM), serum free kappa and lambda, SPEP with M -protein 
quantification, and urine immunofixation electrophoresis must be obtained within [ADDRESS_110116] demonstrate a difference in the involved serum free light chains (kappa or lambda) versus the uninvolved serum free light chain of ≥ 4.5mg/dL 
within [ADDRESS_110117] objective organ involvement defined by [CONTACT_99956] (or more) of the following. All disease for involved organs must be assessed at baseline (defined 
as within 28 days prior to registration)  and must be documented on the AL Baseline 
Tumor Assessment Form.   Note that the following organ disease assessments are 
required if there is suspected involvement of the organ(s). O nly one organ is 
required to be involved for the patient to be eligible for the study.   Assessment  of 
 S1702  
 Page 17  
 Version Date 7/10/19  
  
each organ at baseline is not required if organ involvement is not suspected (see 
Section 9.[ADDRESS_110118] -activation requirements) . 
 
1. Kidney : Albuminuria greater than or equal to 500 mg per day on a 24- hour 
urine specimen, O R prior kidney biopsy (at time of diagnosis) showing 
amyloid deposition;  
 
2. Heart : Mean left ventricular wall thickness on echocardiogram greater than 
or equal to 12 mm in the absence of hypertension or valvular heart 
disease, OR NT -pro BNP greater than 332 pg/mL provided that patient 
does not have impaired renal function (as defined by [CONTACT_99957] 25 mL/min), OR prior cardiac biops y (at time of 
diagnosis) showing amyloid deposition with past documented or presently 
noted clinical symptoms and signs supportive of a diagnosis of heart failure in the absence of an alternative explanation for heart failure;  
 
3. Liver  involvement : Hepatomegaly (total liver  span >15cm) as 
demonstrated by [CONTACT_4654], ultrasound,  or MRI OR  elevated alkaline 
phosphatase ( ALP) greater than 1.5 times the upper limit of normal, OR 
prior liver biopsy (at time of diagnosis) showing amyloid deposition;  
 
4. Gastrointestinal tract : For patients with suspected baseline GI involvement 
(prior biopsy showing amyloid deposition AND symptoms such as GI 
bleeding or persistent diarrhea [> 4 loose stools/day on most days over a  
consecutive 28- day period]), a 24- hour fecal fat test must be obtained at 
baseline . 
 
5. Autonomic or peripheral nervous system : Orthostatic symptoms including 
dizziness or light -headedness with standing, nausea, early satiety, 
diarrhea or constipation, abnormal sensory and/or motor findings on neurologic exam, or gastric atony by [CONTACT_99958]. Patients 
suspected to have neurologic involvement, must have  neurologic 
assessment including orthostatic measurements at baseline.   NIS score at 
baseline is also suggested as a clinical tool for measurement of peripheral neuropathy, but it is not required.   NCS/EMG studies are not required and 
can be obtained as cl inically indicated.   Orthostatic measurements must 
be repeated on 2 separate occasions (at least 1 day apart; e.g., Day -3 
and Day -1). 
 
6. Soft tissue: Macroglossia, or soft tissue deposits (including 
lymphadenopathy, recurrent peri- orbital purpura, per i-articular, skin or 
other soft tissue) requiring therapy. Imaging (CT, MRI, or ultrasound) is 
not required but may be performed as clinically indicated to measure soft 
tissue  involvement . 
 
e. Patients must not have active symptomatic multiple myeloma, as defined by 2015 IMWG criteria (CRAB criteria; bone marrow plasmacytosis >  60%). kappa: lambda 
ratio >100 is acceptable only if the clinical symptoms and sign are attributable only 
to amyloidosis and not multiple myeloma (Hgb < 8g/dL) .  (15) 
 
5.2 Prior/Concurrent Therapy Criteria  
 
a. Patient must be relapsed or refractory to at least  one prior line of therapy  (such 
as: transplant, radiation, or chemotherapy) . 
 
 S1702  
 Page 18  
 Version Date 7/10/[ADDRESS_110119] completed other systemic therapy ≥ 14 days or investigational 
drug ≥ 28 days prior to registration, surgery (other than biopsies) ≥ 21 days prior 
to registration, and any autologous stem cell transplant (ASCT) ≥ [ADDRESS_110120] (such as: doxycycline; curcuramin; prednisone; 
dexamethasone; epi[INVESTIGATOR_99907] [ EGCG ]) within [ADDRESS_110121] not be eligible for autologous stem cell transplantation  as 
determined by [CONTACT_99959]/refused.  
 
5.3 Clinical/Laboratory Criteria  
 
a. Patients must have a complete medical history and physical exam within [ADDRESS_110122] be ≥ [ADDRESS_110123] adequate hepatic function within 28 days prior to registration, 
as defined by [CONTACT_716]:  
 
Total bilirubin ≤ 2.[ADDRESS_110124] (institutional upper limit of the norm)  (patients with 
Gilbert's Syndrome must have a total bilirubin less than 3.0 mg/dL)  
 
AND 
SGOT/AST and SGPT/ALT ≤ 4.[ADDRESS_110125] adequate renal function, as defined by:  
 
• Creatinine clearance (CrCl ) ≥ 25 mL/min., as measured by a 24- hour 
urine collection or as estimated by [CONTACT_99960]. 
The serum creatinine value used in the calculation must have been obtained within 28 days prior to registration.   
Estimated creatinine clearance =  
(140 - age) x wt (kg) x 0.85 (if female)  
72 creatinine (mg/dl)  
e. P atients must have bone marrow aspi[INVESTIGATOR_99908] 35 days prior to 
registration.  The following are required:  
• quantitative percent clonal plasma cell involvement,  
• standard immunophenotypi[INVESTIGATOR_007],  
• immunohistochemistry ,  
• cytogenetics,  
• fluorescent in situ hybridization (FISH) (via participating site local 
laboratory) to assess for del 17p; t11;14; t4;14, t14;16; and del 13q.  
 
 S1702  
 Page 19  
 Version Date 7/10/19  
  
Additionally, FISH and cytogenetic testing (normal – XY; and all abnormalities) are 
required to have been performed and to be reported, even if “no results” was 
achieved (i.e. due to too few cells in specimen).   If FISH was performed, then the 
patient is eligible.  If FISH was not performed,  then patient is not eligible.  Central 
pathology analysis will not be required, however the local pathology report and 
FISH/Cytogenetic data must be submitted in Medidata RAVE.  
 
f. Patients must have adequate bone marrow function as defined by [CONTACT_15211] 28 days prior to registration: ANC ≥ 1,000 cells/mcl without growth factor 
support, AND platelets ≥ 75,000 cells/mcl.  
 
g. Patients must have hemoglobin ≥ 8 g/dL within [ADDRESS_110126] adequate cardiac function as defined by [CONTACT_716]:  
• [LOCATION_001] Heart Association (NYHA) < Class IV heart failure (see 
Section 
18.2); and  
• LVEF by [CONTACT_18585]  ≥ 35% within 28 days prior to registration; and  
• NT-proBNP ≤ 8500 pg/ mL within [ADDRESS_110127] a Zubrod Performance Status ≤ 2.  
 
j. Patients must not have any clinically significant uncontrolled systemic illness, including but not limited to uncontrolled, active infection requi ring intravenous 
antibiotics, unstable angina pectoris, myocardial infarction within the past 6 
months, uncontrolled cardiac  arrhythmias, uncontrolled hypertension, or 
uncontrolled diabetes mellitus.  
 
Uncontrolled diabetes : Patients who have a diagnosis of diabetes must have an 
Hb A1C < 7% within [ADDRESS_110128] three months.  
 Uncontrolled blood pressure and hy pertension: All blood pressure 
measurements within the [ADDRESS_110129] be SBP ≤ 160 and DBP 
≤ 100. An exception can be made by a healthcare provider for a patient with a single blood pressure elevation who upon rechecking has a blood pressure  within 
the parameters above.  
• See ACCF/AHA.AMA- PCPI [INVESTIGATOR_99909]   
 
k. Females of childbearing potential must have a negative baseline pregnancy test 
within [ADDRESS_110130] 50 mIU/mL. Females of childbearing potential 
(FCBP) must also agree: (1) to have a pregnancy test prior to the start of each 
treatment cycle and (2) to either commit to continued abstinence from heterosexual 
intercourse or to use effective contraception while receiving study drug and for at 
least [ADDRESS_110131] dose of study drug. Females are considered to be of “childbearing potential” if they have had menses at any time in the 
preceding 24 consecutive months. In addition to routine contraceptive methods, 
“effective contraception” also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side- effect of pregnancy prevention) defined as a 
hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, she is 
responsible for beginning contraceptive measures.  Men must agree to use a  
condom with either cap, diaphragm or sponge with spermicide (double barrier 
 S1702  
 Page 20  
 Version Date 7/10/19  
  
method)  during sexual contact [CONTACT_4490] a FCBP, even if they have had a successful 
vasectomy  for the study duration and for 12 weeks after the discontinuation of  
treatment.   
 
l. Patients with evidence of Hepatitis B Virus ( HBV) are eligible provided there is 
minimal hepatic injury and the patient has undetectable HBV on suppressive HBV 
therapy.  Patient must be willing to maintain adherence to HBV therapy.  Patients 
with previously treated and eradicated Hepatitis C Virus ( HCV ) who have minimal 
hepatic injury are eligible.   
 
m. Patients who are known to be HIV- positive at registration are eligible if at time of 
registration they meet all other protocol eligibility criteria in addition to the following:  
 
1. Patient has undetectable HIV viral load by [CONTACT_99961];  
 
2. Patient is willing to maintain adherence to combination antiretroviral 
therapy;  
 
3. Patient has no history of AIDS defining condition (other than CD4 cell count <  200 mm
3); 
 
4. Patient is otherwise l ikely to have a near normal lifespan if not for the 
presence of relapsed/refractory amyloid.    
 
n. No other prior malignancy is allowed except for the following:  adequately treated 
basal cell or squamous cell skin cancer, in situ  cervical cancer, adequately treated 
Stage I or II cancer from which the patient is currently in complete remission, or 
any other cancer from which the patient has been disease free for at least two 
years . 
 
5.[ADDRESS_110132] sign 
and give written informed consent in accordance with institutional and federal 
guidelines.  
 
b. As a part of the OPEN registration process (see Section 13.4c  for OPEN access 
instructions) the treating institution's  identity is provided in order to ensure that the 
current  (within 365 days) date of institutional review board approval  for this study 
has been entered in the system.  
  6.0 STRATIFICATION FACTO RS 
 
There are no stratification factors.  
  
 S1702  
 Page 21  
 Version Date 7/10/[ADDRESS_110133]. Terri Parker  at 203/737- [ADDRESS_110134]. Vaishali Sanchorawala at 617/638- 8265.   
 
For dosing principles or questions, please consult the SWOG Policy #38 "Dosing Principles for 
Patients on Clinical Trials" . 
 
7.1 General Treatment Instructions  
 
a. Infusion associated reactions (IARs) (mostly Grade 1- 2 and manageable) are very 
common with the first isatuximab dose administration, even in patients  who had 
received prophylaxis (s ee Section 7.1b ).  Extensive clinical experience with 
approved monoclonal antibodies indicates that mild -to-moderat e infusion reactions 
(either allergic, or consisting of cytokine release, which mimics hypersensitivity 
reactions) are common, particularly during the first infusion; the cytokine release syndrome associated with monoc lonal antibodies consists of a pseudo allergic 
Type B (non- immunoglobulin E mediated) reaction.  The IARs associated with 
isatuximab have been occurring most commonly at the first administration, are not dose dependent, and the patients do not appear to sustain sequelae.  Infusion-
associated reactions generally do not cause therapy discontinuation and tend not 
to recur at subsequent administrations of isatuximab, but if an IAR is observed, the patient must also be informed of the potential risk of recurrent  allergic reactions at 
subsequent infusions.  
 
b. In an attempt to mitigate the incidence and severity of IARs, it is recommended 
that the initial infusion rate should not exceed 175 mg of isatuximab per hour.  In 
the absence of an IAR after 1 hour of infusion, the infusion rate can be increased 
by 50 mg/hour increments every 30 minutes, to a maximum of 400 mg/hour.  
Subsequent infusions should be initiated at 175 mg/hour.  In the absence of IAR’s, 
the rate may be increased by 100 mg/hour every 30 minutes, to a maximum of 400 
mg/hour.  
 
NOTE:  This drug requires infusion  mg/hour  
 
In the event of a Grade [ADDRESS_110135] of 
diphenhydramine 25 mg IV and methylprednisolone 100 mg IV (or equivalent).  In the event of a Grade [ADDRESS_110136] infusion: Prior to  infusion obtain vital signs (BP, HR, temp, oxygen saturation 
by [CONTACT_7852]). Repeat every [ADDRESS_110137] hour, then every 30 minutes 
and with each rate change for the duration of the infusion and continue for 30 
minutes after the end of the infusion . 
 S1702  
 Page 22  
 Version Date 7/10/19  
  
 
Second infusion: Prior to  infusion obtain vital signs (BP, HR, temp, oxygen 
saturation by [CONTACT_7852]). Repeat every [ADDRESS_110138] and subsequent infusions: Prior to  infusion obtain vital signs (BP , HR, 
temp, oxygen saturation by [CONTACT_7852]). Repeat every 30 minutes  and with 
each rate change for the duration of infusion and at the end of infusion.  
 
c. Potential Interference with Blood Bank Serologic Tests:  
 The CD38 protein is weakly expressed on the surface of red blood cells. Because 
of this, anti -CD38 antibodies in patients’ plasma can lead to pan- reactivity and thus 
interfere with various blood bank serologic tests. To avoid potential problems with 
blood transfusion, the American Association of  Blood Banks recommends that 
patients being treated with anti- CD38 antibodies have blood type and screen tests 
performed at baseline, after treatment, and each time before blood infusion.   
 
Type and screen patients and notify institutional blood bank before the first 
administration of the drug and repeat prior to any blood product transfusion. RBC antigen screen is recommended but not required, as per institutional blood  bank 
protocol , and a card with blood type will  be carried by [CONTACT_99962]  (see Appendix 18.6
). Baseline type and cross should be used for 
transfusions, as post -treatment blood type does not change but appears different 
due to presence of the CD38 antibody.  
 
d. Strongly recommend that blood pressure is controlled prior to beginning infusion 
on Day 1, Cycle 1, as per American Heart Association standards, preferable SBP 
≤ 140 and DBP ≤ 90. Blood pressure must be SBP ≤ 160 and DBP ≤ 100 on Day 
1 Cycl e 1. 
 
7.2 Pre-Medication  
 
a. P rimary prophylactic treatment with diphenhydramine 25 to 50 mg IV (or by 
[CONTACT_1966]), methylprednisolone 100 mg IV (or equivalent), ranitidine 50 mg IV  (or 
equivalent) , and acetaminophen 650 to 1000 mg orally 15 to 30 minutes (and 
never longer than 60/ minutes) should be administered to all patients prior to the 
isatuximab infusion to minimize the incidence and severity of IAR commonly observed with monoclonal antibodies.  In the event of interruption of infusion due 
to mild or moderate hypersensitivity reaction, patients should additional pre-medication, as indicated in Section 7.1b 
(above).  
 
Patients who do not experience an IAR during the first [ADDRESS_110139] the need for subsequent premedication reconsidered at the discretion of the treating physician (in consultation with the Study Chair s) to avoid unnecessary 
sedation.  Please contact [CONTACT_64362] s at: [EMAIL_1969]
 and 
[EMAIL_1970]  for documentation and consultation on changes 
in subsequent pre- medication.  
 Prophylactic treatment is  commercially available and will not be supplied by [CONTACT_10748].
 
  
 S1702  
 Page 23  
 Version Date 7/10/19  
  
 
b. Antiviral and proton pump inhibitor  
 
All patients should receive an antiviral (such as acyclovir 800 mg orally daily) for 
the duration of the study.  
 
A proton- pump inhibitor will be used to prevent peptic disease. Prevacid 
(lansoprazole) 15 mg orally daily or equivalent is recommended.  
 These medications are commercially available and will not be supplied by [CONTACT_10748]. The treating physician will provide an outpatient prescription for these 
medications.  
 
7.3 Treatment  
 
Agent  Cycle(s) 1 Day(s)  Dose  Route   
  
Isatuximab  1 1, 8, 15, 22  20 mg/kg IV 
 
Isatuximab 3 2 – 24 1, 15  20 mg/kg IV 
 
1 Note:  One cycle = [ADDRESS_110140].  
3 For Cycles 2- 24, C1D1 weight should be used for dosing, unless there is a > 10% change 
in weight . 
 
7.[ADDRESS_110141]  include clinical NYHA evaluation, 2d 
echocardiogram, and serum NT pro- BNP and troponin I or T measurements.  
Echocardiogram results including LVEF, intraventricular septum wall thickness, 
and left ventricular posterior wall thickness, and if possible (though not essential) 
global longitudinal strain (GLS). It is recommended that baseline and subsequent 
echocardiograms are performed at the same location.   
 
b. Renal   
 
Renal evaluation must  include 24- hour urine, including: Total Protein, UPEP with 
M-Spi[INVESTIGATOR_2531], Urine Protein Immunofixation and Creatinine clearance; serum 
creatinine .  If a 24-hour urine specimen is being collected, the UPEP and urine IFE 
can be obtained via the 24 -hour urine.  I f a 24hour urine is not required, then a 
urine random/spot urine sample is adequate for the UPEP and urine IFE on day [ADDRESS_110142]  include clinical assessment of symptoms (nausea, diarrhea, 
early satiety) and orthostatic blood pressure and pulse rate evaluations. See 
Appendix 18.7  for instructions on obtaining orthostatic blood pressure.  Pulse 
should be recorded at the same time as each blood pressure measurement.   
  
 S1702  
 Page 24  
 Version Date 7/10/19  
  
 
d. Peripheral Neuropathy    
To be assessed clinically. Neur ologic Impairment Score ( NIS) score is suggested 
as a tool for measurement of peripheral neuropathy  but is not required. If baseline 
nerve conduction study/electromyogram ( NCS/EMG ) were obtained for evaluation 
of peripheral nervous system , they must  be followed as part of the organ response 
assessments.  See Appendix 18.2  for NIS form.  
 
e. Soft Tissue / Lymph Nodes :  
 
To be assessed clinically; however, if imaging was used at baseline it is suggested 
that follow -up assessments also be by [CONTACT_9661].  
 
f. Liver:  
 Imaging (CT, US or MR I) to document size of liver, serum alkaline phosphatase 
(ALP)  
 
g. Gastrointestinal :  
 
Clinical assessment of GI bleeding, diarrhea; 24- hour fecal fat test  
 
h. Serum Chemistry : 
 
Must include: sodium, potassium, chloride, bicarbonate, blood urea nitrogen, 
creatinine/ CrCl, glucose, total protein, albumin, calcium, total bilirubin, alkaline 
phosphatase, uric acid, and SGOT/AST and SGPT/ALT.  
 
7.5 Criteria for Removal from Protocol Treat ment  
 a. Hematologic progression of disease or symptomatic deterioration (as defined in 
Sections 10.2 and 10.7) . Organ progression (as defined in Section 10.4
) in the 
absence of hematologic progression does not necessitate removal from treatment. 
 
b. U nacceptable toxicity.  
 
c. Treatment delay  >[ADDRESS_110143] not be delayed for any reason > 42 days. F or 
treatment delay of >[ADDRESS_110144]. 
 
 S1702  
 Page 25  
 Version Date 7/10/19  
  
 
8.0 TOXICITIES TO BE MON ITORED AND DOSE MODI FICATIONS  
 
8.1 NCI Common Terminology Criteria for Adverse Events  
 
This study will utilize the CTCAE Version 5.0 for toxicity and serious adverse event 
reporting. A copy of the CTCAE Version 5.0 can be downloaded from the CTEP home page https://ctep.cancer.gov
. All appropriate treatment areas should have access to a copy of 
the CTCAE Version 5.0. 
 
8.[ADDRESS_110145] transfusion, intravenous albumin, intravenous fluids and electrolyte replacement, antiemetics, antidiarrheal medication, g- csf, anti - hypersensitivity 
medications are all allowable as per institutional standards and Section 3 of the protocol.  
 
8.3 Dose Delays  
 
a. No dose reduction is authorized for isatuximab.  
 
b. Cycle delay up to 14 days is allowed, as indicated in Table 1 below .  
 
Any additional delay (beyond 14 days) must be determined in consultation with the 
Study Chair(s),  and documented via email to:  [EMAIL_1969]
 and 
[EMAIL_1970] . The decision to continue treatment will be based 
on potential for continued clinical benefit, as determined jointly by [CONTACT_1963](s) and Study Chair(s).  Treatment may not be delayed for any  reason for 
more than 42 consecutive days.
 
 
c. Within a cycle , an isatuximab administration can be delayed for up to +/-3 days. If 
the dose cannot be administered within  +/- [ADDRESS_110146] be discussed on a 
case by [CONTACT_99963], documented by [CONTACT_20143]: [EMAIL_1969]
 and [EMAIL_1970]. 
 
d. If a patient experiences several AEs and there are conflicting recommendations,  
follow  the most conservative dose delay.  
 
Table 1: Dose Delays for Isatuximab  
  Treatment -related 
Adverse Event  Grade of Event  Management for Isatuximab  
Neutropenia  
 ≤ Grade 1  No change.  
Grade 2  No change.  
Grade 3  Hold isatuximab until ≤ Grade 2.  
Grade 4  Off protocol therapy.  
¹  G-CSF may be used per treating physician discretion 
and institutional guidelines. See Section 8.4 . 
Anemia¹ ≤ Grade 1  No change.  
Grade 2  Hold isatuximab until < Grade 2.   
Grade 3  Hold isatuximab until < Grade 2.   
 S1702  
 Page 26  
 Version Date 7/10/19  
  
  Treatment -related 
Adverse Event  Grade of Event  Management for Isatuximab  
Grade 4  Off protocol therapy.  
¹  Dose delay is not required for anemia , unless 
deemed necessary by [CONTACT_1963]. 
Transfusions and/or erythrocyte stimulating agents 
are allowable.  
All other events  ≤ Grade 1  No change.  
Grade 2  Hold isatuximab until < Grade 2 OR 
patient returns to baseline (where 
patient had a predetermined 
abnormal baseline).   
Grade 3  Hold isatuximab until < Grade 2 OR 
patient returns to baseline (where 
patient had a predetermined 
abnormal baseline).   
Grade [ADDRESS_110147] be used per ASCO 
guidelines http://jco.ascopubs.org/content/24/19/3187.full  and NCCN Guidelines® Myeloid 
Growth Factors  
http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf . 
 
8.5 Guid elines for the Management of Infusion Reactions (IRs ) 
 Patients should routinely receive premedications prior to isatuximab infusion to reduce the 
risk and severity of IARs commonly observed with monoclonal antibodies. Infusion associated reactions are defined as AEs related to isatuximab with onset typi[INVESTIGATOR_16195] 
24 hours from the start of the infusion.  
 
Patients presenting Grade 2 IAR(s) with infusion interruption may subsequently resume 
isatuximab at half of the initial infusion rate under close monitoring and supportive care as needed. These patients must be informed of the potential risk of recurrent infusion reactions upon rechallenge.  For further infusions, patients may receive additional 
premedication per the judgment of the Investigator. Additional recommended premedications include diphenhydramine 25 mg IV (or equivalent) and methylprednisolone 
100 mg IV.  
 
Once a G rade 2 IAR leading to interruption has improved to Grade ≤1, the infusion may be 
restarted at half the original infusion rate. If symptoms do not recur after 30 minutes, the infusion rate may be increased in 50 mg/hour increments every 30 minutes, to a max imum 
of 400 mg/hour.  
 Patients presenting Grade 3 or 4 isatuximab IAR(s) must have isatuximab permanently discontinued and appropriate supportive therapy should be administered. The IAR(s) and the therapy administered must be documented in the eCRF.
 
  
 S1702  
 Page 27  
 Version Date 7/10/19  
  
 
Table  2 - Management of infusion associated reactions  
 
CTCAE Version 5.0 criteria definition  Intervention recommendation 
Mild (Grade 1) 
Infusion interruption or intervention not indicated  Continuation of isatuximab infusion per the judgment of the Investigator following close direct monitoring of the patient’s clinical status. Isatuximab infusion may be stopped at any time if deemed necessary. If stopped, IAR will be classified as Grade 2 as per CTCAE Version 
5.0.  
Moderate (Grade  2) 
Therapy or infusion interruption indicated, but responds promptly to symptomatic treatment (eg, antihistamines, NSAIDs, narcotics, IV fluids); prophylactic medications indicated for ≤  24 hours  Stop isatuximab infusion. Give additional premedication with diphenhydramine 25 mg IV 
(or equivalent) and/or methylprednisolone 100 mg  IV (or equivalent) as needed. 
Isatuximab may be resumed only after patient recovery, with slower infusion rate and with close monitoring.  
Severe or life -threatening  
(Grade 3 or 4) 
Grade 3: prolonged (eg, not rapi[INVESTIGATOR_20309]/or brief interruption of infusion); 
recurrence of symptoms following initial 
improvement; hospi[INVESTIGATOR_374] f or 
clinical sequelae  
Grade 4: life-threatening consequences; 
urgent intervention indicated Stop isatuximab infusion. Give additional premedication with diphenhydramine 25 mg IV 
(or equivalent) and/ or methylprednisolone 100 mg  IV (or equivalent) and/or epi [INVESTIGATOR_99910]. Definitive treatment discontinuation.  
 
Note: infusion should be completed within 16 hours from the end of infusion preparation or a 
new infusion should be prepared with the remaining dose to be administered the same day.  
Abbreviations:   AE = adverse event; IAR  = infusion associated reaction; IV  = intravenous; 
NCI-CTCAE  = National Cancer Institute Common Terminology Criteria for Adverse Events; 
NSAIDs  = nonsteroidal anti -inflammatory drugs.  
 
8.[ADDRESS_110148]. Terri Parker  at 203/737- [ADDRESS_110149]. Vaishali Sanchorawala at 617/638- 8265.  
 
8.7 Adverse Event Reporting  
 
Toxicities (including suspected reactions) that meet the expedited reporting criteria as 
outlined in Section 16.[ADDRESS_110150] be reported to the Operations Office, Study 
Chair and NCI via CTEP -AERS, and to the IRB per local IRB requirements . 
 
 S1702  
 Page 28  
 Version Date 7/10/19  
 
  
9.0 STUDY CALENDAR  
 
   PRE-STUDY  
(w/in 28 days 
prior to 
registration, 
unless 
otherwise 
noted)  Cycle Length = 28 days  
(+/- 3 days)  Off TX  
Pre-
Progression 
FU Post 
Progression 
FU  REQUIRED 
STUDIES  Cycle 1  Cycle 2  Cycle 3  Cycle 4  Subsequent  
Cycles up to 24 
Cycles 
  
 PHYSICAL   
 History and Physical 
Exam O X X X X X X   
 Height  X               
 Weight  
 X X  X  X  X X   
 Performance Status  X X X X X X     
 Toxicity Notation    X (Days 1, 8, 15, 
22) X (Days 
1, 15)  X (Days 1, 15)  X (Days 1, 
15) X (Days 1, 15)  XQ XQ 
 NYHA Assessment 
K  X X X X X X X   
 Vital Signs N X X  X  X  X  X  X   
 Clinical autonomic 
neurologic evaluation 
A, H X X (every 2 
cycles, +/ - 7 
days)    X (every 2 
cycles, +/ - 7 
days)    X (every 2 
cycles, +/ - 7 
days)  X (every 6 
months, +/ - 
21 days)    
 Clinical peripheral neurologic evaluation 
A, H, K X X (every 2 
cycles, +/ - 7 
days)    X (every 2 
cycles , +/- 7 
days)    X (every 2 
cycles , +/- 7 
days)  X (every 6 
months, +/ - 
21 days)    
 Clinical GI evaluation 
A, H, K X X (every 2 
cycles , +/- 7 
days)    X (every 2 
cycles , +/- 7 
days)    X (every 2 
cycles , +/- 7 
days)  X (every 6 
months, +/ - 
21 days)    
  LABORATORY          
  Type and screen 
and blood bank 
notification E X               
  CBC w/ differential, Platelets 
C X X (Days 1, 8, 15, 
22) X (Days 
1, 15)  X (Days 1, 15)  X (Days 1, 
15) X (Days 1, 15)      
 Serum Chemistry C, 
J, K X X (Days 1, 8, 15, 
22) X (Days 
1, 15)  X (Days 1, 15)  X (Days 1, 
15) X (Days 1, 15)      
 S1702  
 Page 29  
 Version Date 7/10/19  
 
  
   PRE-STUDY  
(w/in 28 days 
prior to 
registration, 
unless 
otherwise 
noted)  Cycle Length = 28 days  
(+/- 3 days)  Off TX  
Pre-
Progression 
FU Post 
Progression 
FU  REQUIRED 
STUDIES  Cycle 1  Cycle 2  Cycle 3  Cycle 4  Subsequent  
Cycles up to 24 
Cycles 
  
 TSH, free T4, free 
T3 J X               
 HIV, HBV, HCV R X               
 PT/PTT/INR L, P X X X X X X     
 RESPONSE ASSESSMENT                
 Serum β2 
microglobulin, LDH, 
uric acid J X               
 Serum Quantitative 
Immunoglobulins 
(IgG, IgA, and IgM)  X               
 SPEP with M -
protein 
quantification  X X X X X X X   
 Serum free kappa 
and lambda light 
chains  X X X X X X X   
 Serum 
Immunofixation  X X X X X X     
 Urine Protein 
Electrophoresis K X X X X X X     
 Urine 
Immunofixation 
Electrophoresis  K X X X X X X     
 Troponins (T or I) A,L X X X X X X X   
 NT-pro-BNP L X X X X X X X   
 Urine or Serum 
Pregnancy F X X X X X X     
 S1702  
 Page 30  
 Version Date 7/10/19  
 
  
   PRE-STUDY  
(w/in 28 days 
prior to 
registration, 
unless 
otherwise 
noted)  Cycle Length = 28 days  
(+/- 3 days)  Off TX  
Pre-
Progression 
FU Post 
Progression 
FU  REQUIRED 
STUDIES  Cycle 1  Cycle 2  Cycle 3  Cycle 4  Subsequent  
Cycles up to 24 
Cycles 
  
 24-hour urine A, H, K X X (If obtained 
w/in 28 days 
prior to C1D1, 
tests need not 
be repeated.)    X   X X   
 Bone Marrow 
Aspi[INVESTIGATOR_99911], 
including FISH, Cytogenetics and 
Immunophenotypi[INVESTIGATOR_007]  X (w/in 35 
days)                
 24-hour fecal fat  A,G X  X (If obtained 
w/in 28 days 
prior to C1D1, 
tests need not 
be repeated.)      X (every 3 
cycles , +/- 7 
days)  X (every 3 
cycles , +/- 7 
days)  X (every 6 
months, +/ - 
21 days)    
 X-RAYS AND SCANS  
 Ultrasound, MRI or 
CT for Disease  
Assessment of liver, 
soft tissue or lymph 
nodes A,I X X (If obtained 
w/in 28 days 
prior to C1D1, 
tests need not 
be repeated.)        X (every 6 
months, +/ - 21 
days)  X (every 6 
months, +/ - 
21 days)    
 12-lead EKG  X X (Days 1, 15)  X           
 2D ECHO G, K X X (If obtained 
w/in 28 days 
prior to C1D1, 
tests need not 
be repeated.)      X (every 3 
cycles, +/- 
7 days)  X (every 3 
cycles, +/- 7 
days)  X (every 6 
months, +/ - 
21 days)    
 SPECIMEN SUBMISSION  
 Optional Peripheral 
Whole Blood, 
Serum. Bone Marrow Aspi[INVESTIGATOR_337] X             
  
 S1702  
 Page 31  
 Version Date 7/10/19  
 
  
   PRE-STUDY  
(w/in 28 days 
prior to 
registration, 
unless 
otherwise 
noted)  Cycle Length = 28 days  
(+/- 3 days)  Off TX  
Pre-
Progression 
FU Post 
Progression 
FU  REQUIRED 
STUDIES  Cycle 1  Cycle 2  Cycle 3  Cycle 4  Subsequent  
Cycles up to 24 
Cycles 
  
and Biopsy Core for 
Banking B 
NOTE:  Forms are found on the protocol abstract page on the SWOG website ( www.swog.org ) and on the CTSU website 
(www.ctsu.org ).  
Forms submission guidelines are found in Section 14.0 . Click here for footnotes . 
NOTE  Unless indicated otherwise in the protocol, scheduled procedures and assessments (treatment administration, 
toxicity assessment for continuous treatment, disease assessment, specimen collection and follow -up 
activities) must follow the established SWOG guidelines on the allowed protocol visits/treatment window as 
outlined in https://www.swog.org/sites/default/files/docs/2017- 10/Best%20Practices%20upddate.pdf . SWOG 
Best Practices allows for a +/ - 3 day window for 28 day cycles.  
 
   
 S1702  
 Page 32  
 Version Date 7/10/19  
 
  
 
 
Footnotes for Calendar 9 (Isatuximab)  
 
A Tests are to be performed per  Section 5.1d  for suspected organ involvement.  If baseline test was performed and abnormality  
 present, the tests will be repeat until off tx prior to progression.   
B See Section 15.[ADDRESS_110151].  
F For women of childbearing potential, prior to beginning treatment at each cycle (or up to 3 days prior to Day 1).  
G If required: Day 1 of Cycles 1, 4, and 7, then every 3 cycles (+/ - 7 days) during treatment, then every 6 months (+/ - 21 days)  
hematologi c progression.  
H If required: Day 1 of Cycles 1, 3, 5, then every 2 cycles (+/ - 7 days) until completion of treatment, then every 6 months  
 (+/- 21 days) until hematologic progression.  
I If required: Every 6 months during and after treatment until hematologic progression, then as clinically indicated.  
J TSH with reflex to free T4, and free T3 uric acid and LDH are required only when clinically indicated; however, baseline  
 testing is encouraged to assess for thyroid involvement, if suspected.  
K See Section 7.4  for a detailed description of organ evaluation and 24 hour urine collection assessment criteria, including  
 serum chemistry panel requirements. All evaluations will continue at specified intervals until one of the criteria for removal from  
 protocol treatment has been met (see Section 7.5 ).   
L If required: Day 1 (+/ - 3 days) of each cycle.  
M See treatment plan Section 7.[ADDRESS_110152] include assessment of soft tissue and lymph nodes, if present at baseline; see Section 7.4e . 
P May be either INR or PT and PTT.  Whichever is performed at baseline should be used throughout treatment.  
Q Assessments should continue until resolution of all acute adverse events.  
R Only required per Section 5.3 Eligibility . 
 
 
  
 
 S1702  
 Page 33  
 Version Date 7/10/19  
 
  
10.0 CRITERIA FOR EVALUAT ION AND ENDPOINT ANA LYSIS 
 
10.1 Measurable diseas e 
 
For the purpose of measuring hematologic response, measurable disease is defined as : 
 
a. Positive monoclonal serum immunofixation electrophoresis or urine 
immunofixation electrophoresis,  
 
and/or  
 
b. Serum free light chain ratio outside of normal range (normal range: 0.25 – 1.65)  
 
10.[ADDRESS_110153] be made by [CONTACT_99964].  
 
a. Hematologic response: (16,17) 
 
1. Complete Response (CR):  
CR is defined as laboratory values within the normal range free light chain 
(FLC) ratio (0.25 – 1.65) and negative serum and urine immunofixation (as 
per institutional laboratory values).  
 2. Very Good Partial Response (VGPR):  
A VGPR is defined as the difference between involved and uninvolved FLCs [dFLC] < 4.0 mg/dL.  
 
3. Partial Response (PR):  
Partial Response is defined as a dFLC decrease of  ≥ 50%, but remaining 
> 4.0 mg/dL 
 
b. Hematologic progression: 50% increase from nadir, or from baseline (if there was 
no response) in any ONE OR MORE of the following:  (18) 
 
1. Serum M- protein:  50% increase in Serum M protein to  a value greater than  
0.5 g/dL. 
 
2. Urine M protein: 50% increase in Urine M protein to a value greater than  
200 mg/day (a visible peak must be present ) 
 
3. Free light chain increase of 50% to a value greater than 10 mg/dL 
 
c. Stable Disease:  
Patients who do not meet criteria for objective response or progression (see 
Sections 10.2a and 10.2b ) will be termed to have stable disease.  
 
10.3 Organ Response (19) 
 
Response to therapy in terms of improvement in organ dysfunction will be defined based 
on functional improvement in one or more involved organ systems. Only [ADDRESS_110154] observation of response.  
  
 S1702  
 Page 34  
 Version Date 7/10/19  
 
  
 
a. Liver response requires either:  
 
1. A 50% decrease in (or normalization of , <1.[ADDRESS_110155] ) alkaline phosphatase 
level, or   
 
2. A reduction in the span of the liver by [CONTACT_2669] 2 cm by [CONTACT_99965].   
 
b. Renal response is defined as either: (20) 
 1. A 30% decrease in urine total albumin; or   
 
2. A decrease to less than 500 mg/24 hours urine total protein  without renal 
progression (where renal progression is defined in Section 10.4a.1
). 
 
c. Gastrointestinal response is defined as either:  
 
1. Reduction in 24- hour fecal fat excretion by ≥ 50% in patients with 
steatorrhea; or  
 2. ≥ 50% reduction in number of loose stools per day in patients with diarrhea.  
  
d. Cardiac response is defined as either: (21) 
 
1. NT-proBNP response (>30% decrease and at least 300 p g/mL decrease 
is needed from the baseline result if NT - proBNP > 650 pg/mL at baseline) 
or 
 
2. NYHA class decrease from 1 to 0; 2 to 1 or 0 or from 3 to 1 (2 class 
decrease if baseline NYHA III) . (That is, If NYHA is 1 or 2, a 1- class level 
drop is required. If NYHA is a 3, a 2- class level drop is required.)  
 
e. A neurologic response is defined as:  
 
1. Clear improvement in neuropathy (peripheral or autonomic) in the opi[INVESTIGATOR_99912]. For peripheral neuropathy, the Neuropathy 
Impairment Tool – Lower Limbs (NIS-LL) must be used to assess 
response.   
 
The NIS (LL is a scoring system graduated from 0 points (the normal 
finding) to a maximum of 88 points (the absence of all motor, sensory, and 
reflex activity in the lower extremities). The scale is additive of all deficits (64 potential points for muscle strength, 8 points for reflexes, and 16 points for sensory function) in the lower extremities. A NIS-LL score 
demonstrating a decrease from baseline of ≥ 2 points  is indicative of organ 
response. (22) 
 See Section 18.2
. 
 
2. For autonomic neuropathy, a clear improvement in the opi[INVESTIGATOR_99913] (systolic 
blood pressure (SBP)) readings and symptoms of dizziness and nausea 
on 2 separate occasions . 
 
 S1702  
 Page 35  
 Version Date 7/10/19  
 
  
a. Orthostatic hypotension is defined as a decrease in systolic blood 
pressure of 20 mm Hg or a decrease in diastolic blood pressure 
of 10 mm Hg within three minutes of standing when compared with blood pressure from the sitting or supi[INVESTIGATOR_2547]. Orthostatic 
symptoms include dizziness, lightheadedness, nausea  
 
f. Soft tissue /lymph nodes : There is no reliable method for assessing soft tissue 
responses.  Determination of soft tissue response will be performed by [CONTACT_99966]/Medical Monitor. Examples of soft tissue responses would include decreased size and thickness of tongue, or improved 
tongue mobility, on physical examination (for macroglossia); objective decrease in 
size of soft tissue deposits on examination or imaging.  
  
10.[ADDRESS_110156] be met to be termed as organ progression 
for the purpose of this study:  
 
1. Renal:  A 50% increase (at least 1 g/day) of 24- hour urine protein to > 1 
g/day OR 25% worsening of serum  creatinine or creatinine clearance 
(Cockcroft -Gault method).  
 
2. Hepatic progression is defined by [CONTACT_5640]:  
 
a. A 50% increase of alkaline phosphatase level above lowest level, 
or  
 
b. An increase in liver span by [CONTACT_2669] 2 cm (radiographic 
determination).  
 
3. Gastrointestinal: Worsening of diarrhea with an increase 50% of previous 
movements per day (not attributable to the study drug or an alternative explanation in the opi[INVESTIGATOR_021]) or 24- hour fecal fat 
increase by 50%.  
 
4. Cardiac: An increase in cardiac wall thickness by 2 mm or an increase in 
NYHA class by [CONTACT_99967] a decreasing ejection fraction of 10%, or 
an increase in NT -proBNP by > 30% and >300 p g/mL or an increase in 
troponin T or I by > 33%.  
 
5. Neurologic: Clearly progressive neuropathy (peripheral or autonomic) that 
in the opi[INVESTIGATOR_99914].  
 
a. For peripheral neuropathy, the Neuropathy Impairment Tool – 
Lower Limbs (NIS-LL) must be used to assess progression.  
 
The NIS (LL is a scoring system graduated from 0 points (the normal finding) to a maximum of 88 points (the absence of all 
motor, sensory, and reflex activity in the lower extremities). The 
scale is additive of all deficits (64 potential points for muscle 
strength, 8 points for reflexes, and 16 points for sensory function) in the lower extremities.  A NIS- LL score demonstrating an 
 S1702  
 Page 36  
 Version Date 7/10/19  
 
  
increase from baseline of ≥ 2 points is indicative of organ 
progression. (23) 
 
See Section 18.2 . 
 
b. Clear worsening of orthostatic vital signs (SBP) and symptoms of 
dizziness or nausea on 2 separate occasions.  
  
6. Soft tissue /lymph nodes: Clearly progressive macroglossia or 
symptomatic soft tissue deposits.  
 
10.[ADDRESS_110157] documentation of progression, symptomatic deterioration (as defined below), or death due to any cause. Patients last known to be alive 
and progression- free are censored at date of last contact.  
 
Symptomatic Deterioration: The global deterioration of health status requiring discontinuation 
of treatment without objective evidence of progression.  
 10.8 Performance Status  
Patients will be graded according to the Zubrod performance status scale.  
 
POINT  DESCRIPTION  
 0  Fully active, able to carry on all pre- disease performance without restriction.  
 
1  Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g., light housework, office work.  
 
2  Ambulatory and capable of self -care but unable to carry out any work activities; 
up and about more than 50% of waking hours.  
 3. Capable of limited self -care, confined to bed or chair more than 50% of waking 
hours.  
 4  Completely disabled; cannot carry on any self -care; totally confined to bed or 
chair.  
 
 
11.[ADDRESS_110158] the hypothesis that the rate of confirmed overall 
hematologic response (CR+VGPR+PR) to treatment is at most 10% versus the alternative 
that the true hematologic response rate is 30% or greater.  
 S1702  
 Page 37  
 Version Date 7/10/19  
 
  
A two -stage design will be used for patient accrual, with a total of 35 eligible patients who 
are evaluable for hematologic response per the definition in Section 11.2b below . (24)  
Patients who received at least one dose of study drug will be considered evaluable.  
Initially, [ADDRESS_110159] a confirmed response, the treatment may be recommended for further testing in subsequent studies. An estimated 39 patients will be enrolled to this study (includi ng 35 eligible and evaluable 
patients, with 20 enrolled to Stage 1 and 15 enrolled to Stage 2, and with an additional 4 
patients enrolled overall to account for ineligible and unevaluable patients).  
 
With an estimated accrual rate of 1- 2 patients per month, it is anticipated that the study will 
reach full accrual in 20 to 40 months . 
 
11.2 Sample size and Power Justification  
 
a. Assuming the number of hematologic responses is binomially distributed this 
design has a significance level of 2% and a power of  87% for detecting a true 
overall hematologic response rate of at least 30% versus the null hypothesis 
response rate of 10% of less.  
 
b. All eligible patients who receive any study treatment will be considered to be 
evaluable for response and toxicity, and will be included in the analysis.   
 
c. Patients who go off study or die prior to the first response assessment will be considered as non- responders.  
 11.3 Analysis of Primary Endpoint  
 
The primary endpoint of this study is overall confirmed hematologic response rate (ORR) , 
which includes partial response (PR), very good partial response (VGPR) and complete response (CR) as defined in Section 10.2.
  
 
Hematologic response will be  reported with a binomial confidence interval.  All eligible 
patients who received at least one day of treatment, including those that go off study or die 
prior to the first response evaluation, will be included in the calculation of response rates.  
The null hypothesis of a response rate of 10% or lower will be evaluated as described 
above, with potential adjustments to the critical values once the exact number of patients 
is determined.  
 
11.[ADDRESS_110160] 5% probability is likely to be observed at least once ( 83% 
chance).  With 35 eligible patients, response rates and rates of individual toxicities can be 
estimated to within +/ - 17% (95% confidence interval).  
 
Organ response will be evaluated in the subset of patients with evaluable organ 
involvement using current criteria Organ involvement will be considered evaluable if it 
qualifies based on the criteria defined in Section 10.3 .  There may be eligible patients 
whose organ involvement is based upon a feature (such as amyloid deposition or certain types of soft tissue involvement) that does not have an associated response/progression 
 S1702  
 Page 38  
 Version Date 7/10/[ADDRESS_110161] completed one cycle of 
treatment or experienced one of the events listed below.  
  
Events to be monitored during safety run- in: 
 
• Grade 3 and  4 infusion- associated reaction (IARs) defined as anaphylactic 
reaction, hypertension, or dyspnea.  
• Grade 4 cardiac event (including CHF and arrhythmias) (or > 2 NYHA grades higher than patient baseline)  
• Grade 4 neutropenia or thrombocytopenia that does not resolve to < Grade 
3 within 10 days  
• Grade 4 infection.  
• Grade 4 gastrointestinal ileus, or obstruction.   
• Grade 4 LFT abnormalities (AST, ALT, Bilirubin)  
 
Reports summarizing adverse events, serious adverse events (SAEs) and treatment 
administration are provided monthly to the Study Chair and Study Statistician for monitoring.  In addition, all SAEs, which by [CONTACT_99968], are reviewed and processed by [CONTACT_99969] a physician reviewer based on data provided via the NCI CTEP -AERS system.  
Cumulative study -specific SAE reports are provided to the Study Chair and Study 
Statistician upon occurrence of an event. Formal reports summarizing the study are prepared for all SWOG members every 6 months.
   
 
 
12.0 DISCIPLINE REVIEW  
 
This study will not utilize discipline review . 
 
  
 S1702  
 Page 39  
 Version Date 7/10/[ADDRESS_110162] be registered prior to initiation of treatment (no more than 5 working days prior to planned start of treatment).  
 
13.2 Investigator/Site Registration 
 
Prior to the recruitment of a patient for this study, investigators must be registered members of a Cooperative Group. Each investigator must have an NCI investigator number and must maintain an “active” investigator registration status through the annual submission of a 
complete investigator registration packet to CTEP.  
 
a. CTEP Investigator Registration Procedures  
 Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) policy require all individuals contributing to NCI -sponsored trials to register 
and to renew their registration annually.   To register, all individuals must obtain a 
Cancer Therapy Evaluation Program (CTEP) Identity and Access Management (IAM) account ( https://ctepcore.nci.nih.gov/iam ).  In addition, persons with a 
registration type of Investigator (IVR), Non- Physician Investigator (NPI[INVESTIGATOR_6731]), or 
Associate Plus (AP) (i.e., clinical site staff requiring write access to OPEN, RAVE, or TRIAD or acting as a primary site contact) must complete their annual 
registration using CTEP’s web- based Registration and Credential Repository 
(RCR) < https://ctepcore.nci.nih.gov/rcr >.  Documentation requirements per 
registration type are outlined in the table below  
 
Documentation Required  IVR NPI[INVESTIGATOR_6732] A 
FDA Form 1572      
Financial Disclosure Form      
NCI Biosketch (education, training, 
employment, license, and 
certification)     
 
HSP/GCP training      
Agent Shipment Form (if 
applicable)      
CV (optional)      
 
An active CTEP -IAM user account and appropriate RCR registration is required to 
access all CTEP and CTSU (Cancer Trials Support Unit) websites and applications.   In addition, IVRs and NPI[INVESTIGATOR_99915] 
 S1702  
 Page 40  
 Version Date 7/10/19  
 
  
IRBs covering their practice sites on the FDA Form 1572 in RCR to allow the 
following:  
 
• Added to a site roster  
• Assigned the treating, credit, consenting, or drug shipment (IVR only) 
tasks in OPEN  
• Act as the site- protocol PI [INVESTIGATOR_6734]  
• Assigned the Clinical Investigator (CI) role on the Delegation of Tasks Log (DTL).   
 
Additional information can be found on the CTEP website at < 
https://ctep.cancer.gov/investigatorResources/default.htm  >.  For questions, 
please contact [CONTACT_99970] < [EMAIL_088]
 >. 
 
b. CTEP Associate Registration Procedures  
 
The Cancer Therapy Evaluation Program (CTEP) Identity and Access 
Management (IAM) application is a web- based application intended for use by [CONTACT_99971] (i.e., all  physicians involved in the conduct of NCI -sponsored clinical 
trials) and Associates (i.e., all staff involved in the conduct of NCI -sponsored 
clinical trials).  
 
Associates will use the CTEP -IAM application to register (both initial registration 
and annual  re-registration) with CTEP and to obtain a user account.  
 
Investigators will use the CTEP -IAM application to obtain a user account only. (See 
CTEP Investigator Registration Procedures above for information on registering with CTEP as an Investigator, which must be completed before a CTEP- IAM 
account can be requested.)  
 
An active CTEP -IAM user account will be needed to access all CTEP and CTSU 
(Cancer Trials Support Unit) websites and applications, including the CTSU members’ website.  
 
Additional information can be found on the CTEP website at 
http://ctep.cancer.gov/branches/pmb/associate_registration.htm
. For ques -tions, 
please contact [CONTACT_99972] 
[EMAIL_089] . 
 c. CTSU Registration Procedures  
 This study is supported by [CONTACT_6818] (CTSU).  
 
1. IRB Approval:   
 
Each investigator or group of investigators at a clinical site must obtain IRB approval for this protocol and submit IRB approval and supporting 
documentation to the CTSU Regulatory Office before they can be approved to enroll patients.  Assignment of site registration status in the 
CTSU Regulatory Support System (RSS) uses extensive data to make a 
determination of whether a site has fulfilled all regulatory criteria including 
but not limited to: an active Federal Wide Assurance (FWA) number, an 
active roster affiliation with the Lead Network or a participating 
organization, a valid IRB approval, and compliance with all protocol specific requirements . 
 
 S1702  
 Page 41  
 Version Date 7/10/[ADDRESS_110163] submit a Study Specific 
Worksheet for Local Context (SSW) to the CIRB via IRBManager to 
indicate their intent to open the study locally.  The CIRB’s approval of the 
SSW is then communicated to the CTSU Regulatory Office.  In order for 
the SSW approval to be processed, the Signatory Institution must inform the CTSU which CIRB -approved institutions aligned with the Signatory 
Institution are participating in the study.  
 
2. Downloading Site Registration Documents:   
 
Site registration forms may be downloaded from the S1702 protocol page 
located on the CTSU members’ website.   
 Go to https://www.ctsu.org and log in to the members’ area using your 
CTEP- IAM username [CONTACT_2383]  
 Click on the Protocols tab in the upper left of your screen  
 Either enter the protocol # in the search field at the top of the protocol tree, or  
 Click on the By [CONTACT_56124]  
 Click on the SWOG  link to expand, then select trial protocol S1702 
Click on LPO Documents, select the Site Registration documents link, and download and complete the forms provided.    
 
3. Requirements For S1702 Site Registration:  
 
• CTSU Transmittal Sheet (optional )  
• IRB approval (For sites not participating via the NCI CIRB; local IRB documentation, an IRB- signed CTSU IRB Certification Form, Protocol 
of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption Form, or combination is accepted)  
 
4. Submitting Regulatory Documents:  
 
Submit required forms and documents  to the CTSU Regulatory Office, via 
the Regulatory Submission Portal, where they will be entered and tracked in the CTSU RSS.  
 
Regulatory Submission Portal : www.ctsu.org  (members’ area)  
Regulatory Tab  Regulatory Submission  
 
When applicable original documents should be mailed to:  
CTSU Regulatory Office [ADDRESS_110164]  
Philadelphia, PA [ZIP_CODE]  
Institutions with patients waiting that are unable to use the Portal should 
alert the CTSU Regulatory Office immediately at 1- [PHONE_102] in order 
to receive further instruction and support.  
  
 S1702  
 Page 42  
 Version Date 7/10/19  
 
  
 
5. Checking Your Site’s Registration Status:  
 
You can verify your site registration status on the members’ section of the 
CTSU website.   
 
• Go to https://www.ctsu.org and log in to the members’ area using your 
CTEP- IAM username [CONTACT_2383]  
• Click on the  Regulatory tab at the top of your screen  
• Click on the Site Registration tab  
• Enter your 5- character CTEP Institution Code and click on Go  
 
Note: The status given only reflects compliance with IRB documentation and institutional compliance with protocol- specific requirements as 
outlined by [CONTACT_6819]. It does not reflect compliance with protocol 
requirements for individuals participating on the protocol or the enrolling 
investigator’s status with the NCI or their affiliated networks . 
 
13.[ADDRESS_110165] be referred to during the registration 
but should not be submitted as part of the patient data.  
 
Patient enrollm ent will be facilitated using the Oncology Patient Enrollment Network 
(OPEN).   OPEN is a web- based registration system available on a 24/[ADDRESS_110166] an active CTEP- IAM account (check at < 
https://eapps -
ctep.nci.nih.gov/iam/index.jsp  >) and a 'Registrar' role on either the LPO or participating 
organization roster.  
 OPEN will also ask additional questions that are not present on the SWOG Registration 
Worksheet.  The individual registering the patient must be prepared to provide answers to 
the following questions:  
 a. Institution CTEP ID  
 
b. Protocol Number  
 c. Registration Step  
 
d. Treating Investigator  
 
e. Credit Investigator  
 f. Patient Initials  
 
g. Patient’s Date of Birth  
 
h. Patient  SSN (SSN is desired, but optional.  Do not enter invalid numbers.)  
 
i. Country of Residence  
 
j. ZIP Code  
 
k. Gender (select one):  
• Female Gender  
• Male Gender  
 S1702  
 Page 43  
 Version Date 7/10/19  
 
  
 
l. Ethnicity (select one):  
• Hispanic or Latino  
• Not Hispanic or Latino  
• Unknown  
 
m. Method of Payment (select one):  
• Private Insurance  
• Medicare  
• Medicare and Private Insurance  
• Medicaid  
• Medicaid and Medicare  
• Military or Veterans Sponsored NOS  
• Military Sponsored (Including Champus & Tricare)  
• Veterans Sponsored  
• Self Pay (No Insurance)  
• No Means of Payment (No Insurance)  
• Other  
• Unknown  
 
n. Race (select all that apply):  
• American Indian or Alaska Native  
• Asian  
• Black or African American  
• Native Hawaiian or other Pacific Islander  
• White  
• Unknown  
 
13.[ADDRESS_110167] database.   OPEN can be accessed at 
https://open.ctsu.org, from the OPEN tab on the CTSU members’ side of the 
website at https://www.ctsu.org , or from the OPEN Patient Registration link on the 
SWOG CRA Workbench.  
 
b. Prior to accessing OPEN site staff should verify the following:  
 
• All eligibility criteria have been met  within the protocol stated timeframes 
and the affirmation of eligibility on the Registration Worksheet has been 
signed by [CONTACT_99973].  Site staff should refer to Section 5.0  to verify eligibility.  
 
• All patients have signed an appropriate consent form and HIPAA authorization form  (if applicable).  
 
c. The OPEN  system will provide the site with a printable confirmation of registrati on 
and treatment information.   Please print this confirmation for your records.  
 d. Further instructional information is  provided on the OPEN tab on the CTSU 
members’ side of the website at https://www.ctsu.org or at https://open.ctsu.org
. 
For any additional questions contact [CONTACT_25518] 888/823-5923 or 
[EMAIL_013] . 
  
 S1702  
 Page 44  
 Version Date 7/10/[ADDRESS_110168] be identified as approved for registration.  
 
c. Registrations may not be cancelled.  
 
d. Late registrations (after initiation of treatment) will not be accepted.  
 
 
14.[ADDRESS_110169] page on the SWOG website 
www.swog.org
 and (with the exception of the sample consent form and the Registration 
Worksheet) must be submitted on-line via the Web; see Section 14.3a  for details.  
 14.[ADDRESS_110170]® 
clinical data management system. Access to the trial in Rave is granted through the iMedidata application to all persons with the appropriate roles assigned in 
Regulatory Support System (RSS). To access Rave via iMedidata, you must have 
an active CTEP -IAM account (check at  
https://eapps -ctep.nci.nih.gov/iam/index.jsp
) and the appropriate Rave role (Rave 
CRA, Read -Only, Site Investigator) on either the LPO or participating organization 
roster at the enrolling site.  
 
Upon initial site registration approval for the study in RSS, all persons with Rave 
roles assigned on the appropriate roster will be sent a study invitation e- mail from 
iMedidata. To accept the invitation, site users must log into the Select Login 
https://login.imedidata.com/selectlogin  using their CTEP -IAM user name [CONTACT_25558], and click on the “accept” link in the upper right -corner of the iMedidata 
page. Please note, site users  will not be able to access the study in Rave until all 
required Medidata and study specific trainings are completed. Trainings will be in 
the form of electronic learnings (eLearnings), and can be accessed by [CONTACT_99974].  
 Users that have not previously activated their iMedidata/Rave account at the time of initial registration approval for the study in RSS will also receive a separate 
invitation from iMedidata to activate their account. Account activation instructions 
are located on the CTSU website, Rave tab under the Rave resource materials (Medidata Account Activation and Study Invitation Acceptance). Additional 
information on iMedidata/Rave is available on the CTSU members’ website under 
the Rave tab at www.ctsu.org/RAVE/
 or by [CONTACT_99975] 
888/823-5923 or by e- mail at [EMAIL_013]  . 
 
 S1702  
 Page 45  
 Version Date 7/10/[ADDRESS_110171] ® via the SWOG CRA Workbench.  Go to the SWOG 
web site http://swog.org  and logon to the Members Area using your SWOG Roster 
ID Number and password. After you have logged on, click on Workbenches , then 
CRA Workbench to access the home page for the CRA Workbench and follow the 
link to Rave ® provided in the left -hand navigation panel.  
 
To access the CRA Workbench the following must be done (in order):  
 
1. You are entered into the SWOG Roster and issued a SWOG Roster ID 
Number,  
2. You a re associated as an investigator or CRA/RN at the institution where 
the patient is being treated or followed,  
3. Your Web User Administrator has added you as a web user and has given 
you the appropriate system permissions to view data for that institution.  
 
For assistance with points 1 and 2 call the Operations Office at 210/614- 8808.  For 
point 3, contact [CONTACT_99976] (refer to the "Who is my Web 
User Administrator?" function on the swog.org Members logon page).  
 
14.4 Data Submission Overview and Timepoints   
 
a. WITHIN 7 DAYS OF REGISTRATION : 
 
Submit the following:  
 
Onstudy Form  
 
AL Baseline Tumor Assessment Form  
 Pathology report, confirming AL amyloidosis (as defined in  Section 5.1
)  
 
If organ involvement was assessed by [CONTACT_9256], submit the pathology report 
documenting the involvement (see Section 5.1d ). 
 
If patient has involvement of the liver or lymph nodes, submit radiology reports 
(ultrasound, CT, or MRI) to assess liver and lymph node size at baseline.  
 
See Section 15.0  for specimen submission requirements . 
 
b. WITHIN 35 DA YS AFTER REGISTRATION : 
 
Submit the following:  
 
S1702 Cytogenetics and FISH Analysis  Form.  
 
Institutional Flow Cytometry Report for Immunophenotypi[INVESTIGATOR_6926] S1702 
Immunophenotypi[INVESTIGATOR_99916], FISH Analysis Report, and Bone Marrow 
Aspi[INVESTIGATOR_99917]  
 
c. WITHIN 14 DAYS AFTER EACH CYCLE OF TREATMENT : 
 
Submit the following:  
 
S1702 Treatment Form  
 
 S1702  
 Page 46  
 Version Date 7/10/19  
 
  
S1702 Adverse Event Form 
 
AL Follow Up Tumor Assessment Form  
 
d. WITHIN 30 DAYS OF DISCONTINUATION OF TREATMENT : 
 
Submit the following:  
 Off Treatment Notice  
 
S1702 Treatment Form  
 
S1702 Adverse Event Form 
 AL Follow Up Tumor Assessment Form  
 
e. WITHIN 14 DAYS OF PROGRESSION/RELAPSE: 
 
Submit the S1702 Treatment Form and S1702 Adverse Event Form (if the patient 
was still on protocol treatment),  
 Submit the AL Follow Up Tumor Assessment Form  
 
f. EVERY 6 MONTHS FOR 4 YEARS AFTER REGISTRATION : 
 
Submit the following:  
 Follow Up Form  
 
Late Effects Form (if prior to treatment for progression or relapse or a second primary, and prior to non- protocol treatment, the patient experiences any severe 
[Grade ≥ 3] long term toxicity that has not been previously reported) . 
 
g. WITHIN 14 DAYS OF SECOND MALIGNANCY : 
 
Submit the following:  
 
Follow Up Form  
 
h. WITHIN 4 WEEKS OF KNOWLEDGE OF DEATH : 
 
Submit the Notice of Death and a final S1702 Treatment Form and S1702 Adverse 
Event (if the patient was still on protocol treatment) or Follow -Up Form (if the 
patient was off protocol treatment) documenting death information.  
 
 
15.0 SPECIAL INSTRUCTIONS  
 
15.1 Translational Medicine and Banking ( OPTIONAL ) 
 
Specimens for translational medicine and banking (submitted to the SWOG Biospecimen 
Bank – Solid Tissue, Myeloma and Lymphoma Division- Lab #201) (optional for patient):  
 
a. With patient’s consent, specimens ( peripheral whole blood, serum , bone 
marrow aspi[INVESTIGATOR_99918] ) must be collected prior to 
initiation of protocol therapy . Collection instructions are outlined in Section 15.1b  
and shippi[INVESTIGATOR_99919] 15.1c . (See also  Section 9.0 ): 
 S1702  
 Page 47  
 Version Date 7/10/19  
 
  
 
1. Tissue  (frozen bone marrow biopsy core) : Pretreatment (within 35 days 
prior to registration) .  
 
2. Blood (whole blood and serum) must be fresh drawn prior to treatment on 
Cycle 1, Day 1.  
 
b. Specimen Collection Instructions:  
 
1. Peripheral W hole Blood:  
 
a. Fill one [ADDRESS_110172] 8 to 10 times.  
 
c. Clearly and appropriately label the sample tube (per instructions 
in the STS).  
 
d. Within 30 minutes of collection (after gently mixing),  freeze  
the blood in an upright position at -80ºC for storage until shipment. 
If freezer is not immediately available, samples must be stored on dry ice until shipment.  
 
2. Bone Marrow Aspi[INVESTIGATOR_337]:  
 a. Collect 3 – 4 mL of bone marrow aspi[INVESTIGATOR_99920] a sodium heparin 
(NaHep, green top) tube.  
 
b. Mix gently by [CONTACT_99977] 8 to 10 times.  Do not centrifuge 
and do not freeze.  
 *  Note that marrow specimens should be submitted within 24 hours of 
draw for viability.  
 
3. Bone Marrow Biopsy Core:  
 
a. Biopsy core specimen should be 1 – 2 cm in length.  
 
b. Snap -freeze  immediately after resection.  
 
*  Note that marrow specimens should be submitted within 24 hours of 
draw for viability.  
 
4. Serum:  
 
a. Collect 5 – 7 mL of blood into a red top tube.  
 
b. Allow blood to clot (30 – 60 minutes) before processing.  Refer to 
processing instructions on the SWOG website 
(https://www.swog.org/clinical -trials/biospecimen-
resources/biospecimen- processing- and-submission- procedures .     
 
 S1702  
 Page 48  
 Version Date 7/10/19  
 
  
5. Additional specimen collection, labelling, and shipment  instructions for the 
serum, bone marrow aspi[INVESTIGATOR_99921] S WOG Specimen Submission webpage:  
www.swog.org/clinical -trials/biospecimen- resources/biospecimen-
processing- and-submission- procedures . 
 
6. Specimen collection kits are not being provided for this submission; s ites 
will use institutional supplies.  
  
c. Specimen Labeling  
 
1.   Blood, serum, and bone marrow labels should include:  
• SWOG patient number  
• Patient initials  
• Collection date (date the specimen was collected from the patient)  
• Laterality (bone marrow only – e.g. left, right)  
 
2.    Tissue specimen labels should include:  
• SWOG patient number * 
• Patient initials  
• Collection date (date the specimen was collected from the patient)  
• Collection site (e.g., lymph node)  
• Specify if the tissue is from Primary (P) or Metastatic (M) 
• Surgical Pathology ID (SPID) and Block number (e.g., A2, 3E, 2- 1, 
etc.)  
 
* To obtain a SWOG Patient ID prior to patient registration, go to the 
SWOG specimen tracking system 
(https://crawb.crab.org/TXWB/ctsulogon.aspx ) and select “Specimen 
Tracking.”  Use the “Log a Specimen” link from the Specimen Tracking 
Home page. Use the “No Patient ID yet?” link and enter demographic information for the patient on the next page. This will assign a SWOG patient ID number and will remain the patient’s ID number. If the patient 
does register to the study, it is important to remember to use this patient ID number on the OPEN system so the specimens will match with the correct patient.  Specimens will be destroy ed if the 
patient is not subsequently registered to the study.  
 
d. SHIPPI[INVESTIGATOR_99922]  
 
1. SWOG Specimen Tracking System (STS)  
 
All specimen submissions for this study must be entered and tracked using 
the SWOG online Specimen Tracking system. SWOG members may log on the online system via the CRA Workbench. To access the CRA 
Workbench, go to the SWOG Web site http://swog.org
 and logon to the 
Members Area. After you have logged on using your SWOG roster ID 
number and password, click on the CRA Workbench link to access the 
home page for CRA Workbench website. Non- SWOG users may log into 
SpecTrack using  their CTSU UserID and password on the SpecTrack login 
page located at https://spectrack.crab.org  (select the option “SWOG – 
SWOG – CTSU”).  SpecTrack start -up instructions (both written and 
demo) are available after signing in to SpecTrack.  
 
A copy of the Shipment Packing List produced by [CONTACT_99978] 
 S1702  
 Page 49  
 Version Date 7/10/[ADDRESS_110173] BE LOGGED VIA THIS SYSTEM; THERE ARE NO EXCEPTIONS.  
 
To report technical problems with Specimen Tracking, such as database errors or connectivity issues, please send an email to 
[EMAIL_1193]
. For procedural help with logging and 
shippi[INVESTIGATOR_36406], there is an introduction to the system on the 
Specimen Tracking main page ( https://spectrack.crab.org/Instructions ); or 
contact [CONTACT_99979] 206/652- 2267 to be routed to the 
Data Coordinator for further assistance.  
 
In the online specimen tracking system, the appropriate SWOG laboratory 
for submission of  periphera l whole blood, serum , bone marrow 
aspi[INVESTIGATOR_99923]:  
 
Lab #201:          SWOG Biospecimen Bank  
Solid Tissue, Myeloma and Lymphoma Division   
Phone:    614- 722-[ADDRESS_110174]:  SWOG Bank  Coordinator  
Email:     [EMAIL_1977]   
 
2. Federal guidelines for the shipment of blood products:  
 
a. The tube must be wrapped in an absorbent material.  
 b. The tube must then be placed in an AIRTIGHT container (like a 
resealable bag).  
 
c. Pack the resealable bag and tube in a Styrofoam shippi[INVESTIGATOR_34919].  
 
d. Pack the Styrofoam shippi[INVESTIGATOR_60762] a cardboard box. 
 e. Mark the box "Biohazard".  
 
e. Obtaining SWOG Patient ID Prior to Patient Registration  
 
To obtain a SWOG patient ID for purposes of specimen submission prior to 
registration, use the SWOG specimen tracking system  
(https://crawb.crab.org/TXWB/ctsulogon.aspx
).  Select “Specimen Tracking,” then 
click the “Log a Specimen” link from the Specimen Tracking Home page, and then the “No Patient ID yet?” link.   Enter demographic information for the patient on the 
next page. This will assign a SWOG patient ID number and will remain the patient’s 
ID number. If the patient does register to the study, it is important to remember to 
use this patient ID number on the OPEN system, so the specimens will match with 
the correct patient. Specimens will be destroyed if the patient is not subsequently registered to the study.   Note that patients must sign consent prior to specimen 
submission.  
 
  
 S1702  
 Page 50  
 Version Date 7/10/[ADDRESS_110175] and monitoring of clinical investigations; they also represent sound research practice:  
 
Informed Consent  
The principles of informed consent are described by [CONTACT_60836] (Federal Register Vol. 46, No. 17, January 27, 1981, part 50) and the Office for Protection from Research Risks Reports:  Protection of Human Subjects (Code of Federal Regulations 45 CFR 46).  They must be followed to comply with FDA regulations for the conduct and monitoring of clinical 
investigations.  
 
Institutional Review  
This study must be approved by [CONTACT_99980] (Ref. Federal Register Vol. 46, No. 17, January 27, 1981, part 56) and the Office for Protection from Research Risks Reports:  Protection of Human Subjects (Code of Federal 
Regulations 45 CFR 46).  
 
Drug Accountability  
An investigator is required to maintain adequate records of the disposition of investigational drugs 
according to procedures and requirements governing the use of investigational new drugs as 
described in the Code of Federal Regulations 21 CFR 312.  
 
Monitoring  
This study will be monitored by [CONTACT_470] (CDUS) Version 3.0.  Cumulative protocol - and patient -specific CDUS data will be submitted electronically to CTEP on a quarterly 
basis by [CONTACT_6798].  Reports are due January 31, April 30, July 31, and October 31.  
Instructions for submitting data using the CDUS can be found on the CTEP Web site  
(http://ctep.cancer.gov/reporting/cdus.html).  
 
Note:  If your study has been assigned to CDUS -Complete reporting, all adverse events (both 
routine and expedited) that have occurred on the study and meet the mandatory CDUS reporting 
guidelines must be reported via the monitoring method identified above.  If your study has been 
assigned to CDUS -Abbreviated reporting, no adverse event reporting (routine or expedited) is 
required to be reported via CDUS, but expedited adverse events are still required to be submitted 
via CTEP -AERS.  
 
Confidentiality  
Please note that the information contained in this protocol is considered confidential and should 
not be  used or shared beyond the purposes of completing protocol requirements until or unless 
additional permission is obtained.  
 16.1 Adverse Event Reporting Requirements  
 
a. Purpose  
 
Adverse event data collection and reporting, which are required as part of every  
clinical trial, are done to ensure the safety of patients enrolled in the studies as well as those who will enroll in future studies using similar agents. Adverse events are reported in a routine manner at scheduled times during a trial. 
(Directions for routine reporting are provided in Section 14.0
.) Additionally, 
certain adverse events must be reported in an expedited manner to allow for 
more timely monitoring of patient safety and care. The following guidelines 
prescribe expedited adverse event reporting for this protocol.  
 S1702  
 Page 51  
 Version Date 7/10/19  
 
  
 
b. Reporting method 
 
This study requires that expedited adverse events be reported using the Cancer 
Therapy Evaluation Program Adverse Event Reporting System (CTEP -AERS).  
CTEP's guidelines for CTEP -AERS can be found at http://ctep.cancer .gov. A 
CTEP- AERS report must be submitted to the SWOG Operations Office  
electronically via the CTEP -AERS Web -based application located at  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_
events.htm .  
 
c. When to report an event in an expedited manner  
 
Some adverse events require 24- hour notification (refer to Table 16.1 ) via 
CTEP- AERS.  When Internet connectivity is disrupted, a 24- hour notification is 
to be made to SWOG by [CONTACT_1381] 210- 614-8808, or by [CONTACT_25541] 
[EMAIL_1196].  Once Internet connectivity is restored, a 24- hour notification 
that was made by [CONTACT_99981] [EMAIL_1196]  must be entered electronically 
into CTEP- AERS by [CONTACT_433].  
 
When the adverse event requires expedited reporting, submit the report within the number of calendar days of learning of the event specified in Table 16.[ADDRESS_110176] one dose of the investigational agent(s) as part of the trial. Reporting requirements are provided in Table 16.1
. The investigational agent used in this study  isatuximab 
(SAR650984). If there is any question about the reportability of an adverse event or if on- line CTEP -AERS cannot be used, please telephone or email the 
SAE Specialist at the Operations Office, 210/614- 8808 or 
[EMAIL_1196] , 
before preparing the report.   
 S1702  
 Page 52  
 Version Date 7/10/19  
 
  
Table 16.1:  
Phase 1 and Early Phase 2 Studies:  Expedited Reporting Requirements for Adverse events 
that Occur on Studies under an  Non-CTEP IND within [ADDRESS_110177] Administration of 
the Investigational Agent/Intervention1   Isatuximab ( SAR650984) . 
 
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)  
NOTE:   Investigators MUST  immediately report to the sponsor (NCI) ANY  Serious Adverse Events, 
whether or not they are considered related to the investigational agent(s)/intervention (21 
CFR 312.64)  
An adverse event is considered serious if it results in ANY  of the following outcomes:   
1) Death  
2) A life -threatening adverse event  
3) An adverse event that results in inpatient hospi[INVESTIGATOR_1328] ≥ 24 hours  
4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions  
5) A congenital anomaly/birth defect.  
6) Important Medical Events (IME) that may not result in death, be life threatening, or require 
hospi[INVESTIGATOR_708], based upon medical judgment, they may 
jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6).  
ALL SERIOUS  adverse events that meet the above criteria MUST be immediately reported to the 
NCI via CTEP- AERS within the timeframes detailed in the table below.  
Hospi[INVESTIGATOR_317] 1 and Grade 2 Timeframes  Grade 3-5 
Timeframes  
Resulting in 
Hospi[INVESTIGATOR_059] ≥ 24 hrs  10 Calendar Days  
24-Hour 5 
Calendar Days  Not resulting in 
Hospi[INVESTIGATOR_059] ≥ 24 hrs  Not required  
NOTE:   Protocol specific exceptions to expedited reporting of serious adverse events are found in 
the Specific Protocol Exceptions to Expedited Reporting (SPEER) portion of the CAEPR or Section 16.1f
. 
Expedited AE reporting timelines are defined as:  
o “24-Hour; 5 Calendar Days” - The AE must initially be reported via CTEP- AERS within 24 
hours of learning of the AE, followed by a complete expedited report within 5 calendar 
days of the initial 24-hour report.  
o “10 Calendar Days” - A complete expedited report on the AE must be submitted within 
[ADDRESS_110178] administration of 
investigational agent/intervention and have an attribution of possible, probable, or definite 
require reporting as follows:  
Expedited 24- hour notification followed by [CONTACT_432] 5 calendar days for:  
• All Grade 3, 4, and Grade 5 AEs  
Expedited 10 calendar day reports for:  
• Grade 2 AEs resulting in hospi[INVESTIGATOR_99924] 5, 2011  
 S1702  
 Page 53  
 Version Date 7/10/19  
 
  
f. Additional Instructions or Exceptions to CTEP -AERS Expedited Reporting 
Requirements for Phase 1 and Early Phase 2 Studies Utilizing an Agent 
under a non- CTEP-IND: 
 
1. Group-specific instructions.  
 
Supporting Documentation Submission - Within 5 calendar days 
submit the following to the SWOG Operations Office by [CONTACT_12100] 210- 614-
0006 or mail to the address below:  
• Printed copy of the first page of the CTEP -AERS report  
• Copi[INVESTIGATOR_99925]  
• If applicable, and they have not yet been submitted to the 
SWOG Data Operations Center, copi[INVESTIGATOR_99926]/or Notice of Death.  
 
2. The adverse events listed below also require expedited monitoring for thi s 
trial: 
 
• ≥ Grade 3 infusion- associated reactions ( IARs );  
• Acute IARs Grade 3 or 4. An IAR is an AE related to isatuximab 
typi[INVESTIGATOR_99927] 24 hours from the start of isatuximab infusion  
• Symptomatic overdose (serious or nonserious) with study treatment  
• An overdose (accidental or intentional) with the study treatment is an event suspected by [CONTACT_99982] (not based on systematic pi[INVESTIGATOR_99928]) and defined as:  
• Increase of at least 30% of the dose to be administered in the 
specified duration or if the dose is administered in less than half the 
recommended duration of administration.  
• Of note, asymptomatic overdose has to be reported as a standard 
AE. 
 
3. For study arm(s)  [applicable study arm(s)], the adverse events listed below 
do not require expedited reporting via CTEP- AERS:  None.  
 
g. Reporting Secondary Malignancy, including AML/ALL/MDS  
 
1. A secondary malignancy is a cancer caused by [CONTACT_437] a previous malignancy (e.g., treatment with investigational agent/intervention, radiation or chemotherapy). A secondary malignancy is not considered a 
metastasis of the initial neoplasm.  
  SWOG requires all secondary malignancies that occur following 
treatment with an agent under a Non- NCI IND to be reported via CTEP -
AERS.  Three options are available to describe the event.  
 
• Leukemia secondary to oncology chemotherapy (e.g., Acute 
Myelocytic Leukemia [AML])  
 
• Myelodysplastic syndrome (MDS)  
 
• Treatment -related secondary malignancy  
  Any malignancy possibly related to cancer treatment (including AML/MDS) should also be reported via the routine reporting 
mechanisms outlined in each protocol.  
 
 S1702  
 Page 54  
 Version Date 7/10/19  
 
  
Second Malignancy: A second malignancy is one unrelated to the 
treatment of a prior malignancy (and is NOT a metastasis from the 
initial malignancy).   Second malignancies require ONLY routine 
reporting via CDUS unless otherwise specified.  
 
For more information see:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/d
ocs/aeguidelines.pdf .  
 
2. Any supporting documentation should be submitted to CTEP per NCI 
guidelines for AE reporting located at:   
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/d
ocs/aeguidelines.pdf . 
 
A copy of the report and the following supporting documentation must 
also be submitted to SWOG Operations Office within 30 days by [CONTACT_12100] 
[PHONE_1130] or mail to the address below:  
 
• a copy of the pathology report confirming the AML/ALL /MDS diagnosis  
• (if available) a copy of the cytogenetics report   
 SWOG  
ATTN: SAE Program  
[ADDRESS_110179]  
San Antonio, [LOCATION_007] [ZIP_CODE]  
 
NOTE: If a patient has been enrolled in more than one NCI -sponsored 
study, the report must be submitted for the most recent trial.  
 h. Reporting Pregnancy, Pregnancy Loss, and Death Neonatal  
 
1. Pregnancy Study participants who become pregnant while  on study; that 
pregnancy should be reported in an expedited manner via CTEP -AERS 
as Grade 3 “Pregnancy, puerperium and perinatal conditions – Other 
(pregnancy)”  under the Pregnancy, puerperium and perinatal 
conditions  SOC.   
 
Additionally, the pregnancy outcome for patients on study should be 
reported via CTEP -AERS at the time the outcome becomes known, 
accompanied by [CONTACT_90324].  
 
2. Pregnancy Loss  Pregnancy loss  defined in CTCAE as “Death in utero” . 
Pregnancy loss should be reported expeditiously as Grade 4 
“pregnancy  loss” under the Pregnancy, puerperium and perinatal 
conditions  SOC.   
 A pregnancy loss should NOT be reported as a Grade 5 event under the 
Pregnancy, puerperium and perinatal conditions SOC, as currently CTEP -
AERS recognizes this event as a patient death.  
  
 S1702  
 Page 55  
 Version Date 7/10/19  
 
  
 
3. Death Neonatal Death neonatal is  defined in CTCAE as “Newborn death 
occurring during the first 28 days after birth .   
 
A neonatal death should be reported expeditiously as Grade 4 “General 
disorders and administration – Other (neonatal loss)” under the 
General disorders and administration  SOC.  
 
Neonatal death should NOT  be reported as a Grade 5 event  under the G eneral 
disorders and administration SOC as currently CTEP -AERs r ecognized this event 
as a patient death.  
 NOTE:   When submitting CTEP -AERS reports for “Pregnancy ”, “Pregnancy loss”, 
or “Neonatal loss”, the Pregnancy Information Form should also be completed and faxed with any additional medical information to 301- 230-0159.  The potential risk 
of exposure of the fetus to the investigational agent(s) or chemotherapy agent(s) should be documented in the “Description of Event” section of the CTEP -AERS 
report.  
 
The Pregnancy Information Form is available at:  
http://ctep.ca ncer.gov/protocolDevelopment/adverse_effects.htm . 
 
i. [COMPANY_011] -Direct Additional SAE Reporting Requirements  
 
1.   Pregnancy reporting:  
 
In the event that the partner of a study participant becomes pregnant while the participant is on study treatment, additional reporting of pregnancy information to [COMPANY_011] is requested.    
  In the event of such a pregnancy, the site must make reasonable eff orts 
to obtain consent from the study participant’s partner for pregnancy 
reporting.   The additional consent is the responsibility of the site and must 
take place according to local Institutional Review Board requirements.   A 
sample consent template is included as Appendix 18.[ADDRESS_110180] be reported via the [COMPANY_011] Exposure During 
Pregnancy (EDP) Form.   The form must be submitted directly to [COMPANY_011] 
according to the instructions on the form included in Appendix 18.[ADDRESS_110181] page of the SWOG website 
(www.swog.org) or the CTSU website ( www.ctsu.org
).  Note that this 
additional support is available ONLY to institutions submitting the [COMPANY_011] 
Exposure During Pregnancy Form in the event that a female partner of a 
study participant becomes pregnant.   Pregnancy and outcome information 
submitted via CTEP -AERS performed in accordance with NCI guidelines 
as part of regular  adverse event reporting requirements is not reimbursed.  
 
2.      Additional information 
 
Reporting information provided in the protocol takes precedence over 
information provided in the supplemental reporting requirements.    
 
 S1702  
 Page 56  
 Version Date 7/10/19  
 
  
 
 
17.0 BIBLIOGRAPHY  
1  Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, 
and management. Am J Hematol 86(2): 180- 6, 2011. PMID: 21264900.  
 2  Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high- dose 
melphalan and autologous stem cell transplantation: long- term results in a series of 421 patients. 
Blood 118(16):4346- 52, 2011. PMID:  21828140.  
 
3  Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate- dose 
dexamethasone is an effective but toxic treatment for patients with primary amyloidosis ( AL). Blood 
105:2949- 5, 2005. PMID:  15572585.  
 
4  Sanchorawala V, Skinner M, Quillen K, et al. Long- term outcome of patients with AL amyloidosis 
treated with high- dose melphalan and stem -cell transplantation. Blood 110(10):3561- 3, 2007. 
PMID: 17673601.  
 5  Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin 
light-chain amyloidosis. Blood, 119(23), 5397- 5404, 2012. PMID: 22493299.  
 6  Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with 
the combination of bortezomib and dexamethasone. Haematologica. 92(10):1351- 8, 2007. PMID: 
18024372.  
 
7  Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice- weekly bortezomib in patients 
with systemic AL amyloidosis: results o f a phase 1 dose -escalation study. Blood 114:1489–97, 
2009. PMID: 19498019.  
 
8  Mikhael JR, Schuster SR, Jimenez -Zepeda VH, et al. Cyclophosphamide- bortezomib-
dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL 
amylo idosis. Blood. 10;119(19):4391- 4, 2012. PMID: 22331188.  
 
9  Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment -
refractory multiple myeloma (SIRIUS): an open- label, randomised, phase 2 trial. Lancet. 2016 Apr 
9;387([ZIP_CODE]):1551- 60. Epub 2016 Jan 7. PMID: 26778538.  
 10  Sher T; Fenton B, Gertz, M, et al. First report of safety and efficacy of daratumumab in two cases of advanced immunoglobulin light chain amyloidosis. Blood. http://dx.doi.org/10.1182/blood- 2016-
06-722496. [ADDRESS_110182] U. (Kaufman GP, et al: Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood, 2017).  
 
12  Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in 
immunoglobulin light chain amyloidosis (AL): a consensus opi[INVESTIGATOR_99929] 10th International Symposium on Amyloid and Amyloidosis, Tours, [LOCATION_009], 18- 22 April 2004. Am J Hematol.  
Aug;79(4):319- 28, 2005. PMID:  16044444.  
 13  Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.. J Clin 
Oncol. Feb 20;28(6):1031- 7. doi: 10.1200/JCO.2009.23.8220. Epub 2010 Jan 19, 2010. PMID: 
20085941.  
  
 S1702  
 Page 57  
 Version Date 7/10/[ADDRESS_110183] 9;124(15):2325- 32. doi: 
10.1182/blood- 2014- 04-570010. Epub 2014 Aug 12, 2014. PMID: 25115890.  
 15  Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment 
of multiple myeloma. Leukemia. Jan;23(1):3- 9. doi: 10.1038/leu.2008.291. Epub [ADDRESS_110184] 30, 
2009. PMID: 18971951.  
[ADDRESS_110185] and reporting of 
clinical trials in systemic light -chain amyloidosis. Leukemia 26, 2317– 2325; 
doi:10.1038/leu.2012.100, 2012. PMID: 22475872.  
 17  Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opi[INVESTIGATOR_99929] 10th International 
Symposium on Amyloid and Amyloidosis, Tours, [LOCATION_009], April 18- 22, 2004. Am J Hematol. 
Aug;79(4):319- 328. 2005. PMID:  16044444.  
 [ADDRESS_110186] and reporting of 
clinical trials in systemic light -chain amyloidosis , 2012.100. leu. Epub Apr 5, 2012. PMID:    
22475872. 
 
19  Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opi[INVESTIGATOR_99929] 10th International 
Symposium on Amyloid and Amyloidosis, Tours, [LOCATION_009], April 18- 22, 2004. Am J Hematol. 
Aug;79(4):319- 328. 2005. PMID:    16044444.  
 [ADDRESS_110187] 9;124(15):2325- 32. 2014. PMID: 
25115890.  
21  Palladini G, Dispenzieri, A, Gertz MA. New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. J Clin Oncol. Dec 20;30(36):4541- 9. 2012. PMID: 23091105.  
 22  Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 79(8):785- 92; 2012. PMID: 2 2843282.  
 23  Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 79(8):785- 92; 2012. PMID: 22843282.  
 
24  Green S. and Dahlberg S.  Planned versus attained design in Phase II clinical trials. Statistics in 
Medicine 11:853- 862, 1992  
 
  
 S1702  
 Page 58  
 Version Date 7/10/19  
 
  
 
18.0 APPENDIX  
 
18.1  [LOCATION_001] Heart Association Classifications  
 18.2 Neuropathy Impairment Scale – Lower Limbs  
 
18.[ADDRESS_110188] Pregnancy Reporting Consent  
 18.5 [COMPANY_011] Exposure During Pregnancy (EDP) Form  
 
18.[ADDRESS_110189]  
 
18.7 Measuring Orthostatic Blood Pressure  
  
  
 S1702  
 Page 59  
 Version Date 7/10/[ADDRESS_110190]*  To Work**   
 
I None  None  None  Full Time  
 II Only moderate  Slight  Usually only slight  Usually full time 
   or occasional  
 
III Defined, with less  Marked Usually moderate  Usually part time 
 than ordinary  
 activity  
 
IV May be present  Extreme  Marked Unable to work  
 even at rest, & any  
 activity increases  
 discomfort      
 
* To control or relieve symptoms, as determined by [CONTACT_102], rather than as advised by [CONTACT_099].  
 ** At accustomed occupation or usual tasks.  
  
 S1702  
 Page 60  
 Version Date 7/10/19  
 
  
18.2 Neuropathy Impairment Scale – Lower Limbs  
 
The NIS (LL is a scoring  system  graduated  from 0 points  (the normal  finding)  to a 
maximum  of 88 points  (the absence of all motor,  sensory,  and reflex  activity in the 
lower  extremities). The scale  is additive  of all deficits  (64 potential  points  for muscle  
strength,  8 points  for reflexes,  and 16 points  for sensory  function) in the lower 
extremities.  
 
Instructions:  Complete each assessment outlined  below  and assign  a score  for the 
right side and for the left side.  
 
S1702 Patient ID: ___ ___ ___  __ ___ ___ 
Date of Visit:                                     _____________________  
□ Registration  
□ Cycle ___, Day 1  
□ Post -Treatment (Pre- Hematolgic Progression)  □ Post -Adverse Event Follow -up 
□ Unscheduled Visit  
Assessment  Right Left Sum  
Muscle Weakness Score  each assessment  as: 
0: normal,  1: 25% weakened,  2: 50% weakened,  3: 75%  weakened,  4: paralysis  
Hip Flexion  (iliopsoas)     
Hip Extension  (gluteus  max.)     
Knee  Flexion  (biceps  femoris)     
Knee  Extension  (quadriceps)     
Ankle  Dorsiflexors  (tibialis  ant. +)    
Ankle  Plantar  Flexors  (gastroc.  soleus)     
Toe Extensors     
Toe Flexors     
Reflexes Score  each , assessment  as:  0: normal,  1: reduced,  2: absent  
Quadriceps  femoris     
Triceps  surae/gastroc.  soleus     
Sensation:  Great Toe (terminal  phalanx)  Score  each  assessment  as:  
0: normal,  1: reduced,  2: absent  
Touch  pressure     
Pi[INVESTIGATOR_99930]: _________________  
Source: Dyck  PJ, Litchy  WJ, Lehman  KA, et al. Variables  influencing neuropathic  endpoints:  the [COMPANY_002]ster  
Diabetic  Neuropathy  Study  of Healthy  Subjects.  Neurology . 1995e45(6):1115(21.  
 
Performed by (Print  Name):    _________________________    ___________________  
 
   Date:  / /   
Signature           [CONTACT_99990]  
 S1702  
 Page 61  
 Version Date 7/10/19  
 
  
 
18.3 SWOG Biospecimen Bank Appendix  
 
Specimen Receipt, Processing, and Storage  
 
The SWOG Biospecimen Bank will receive frozen serum, frozen blood, snap- frozen bone 
marrow biopsy, and fresh bone marrow aspi[INVESTIGATOR_337].  
 The Bank will accession and barcode frozen specimens for long- term storage; serum and 
frozen blood will be stored in a -80°C freezer for long- term storage, and the bone marrow 
biopsy will be stored in a liquid nitrogen vapor phase freezer.  
 The fresh bone marrow aspi[INVESTIGATOR_99931] a ficoll -hypaque gradient, and the 
resulting cells wil be sorted (CD138 +/ -), aliquoted into 1 x 10
7 cells per vial, and stored in 
a liquid nitrogen vapor phase freezer until distribution.  
 
Distribution of Specimens from the SWOG Biospecimen Bank to TM Investigators:  
At the end of the study, the Bank will receive a list of specimens for distribution.  
 Frozen Whole Blood will be shipped to the SWOG Biospecimen Bank  for extraction, and 
then forwarded to [COMPANY_011] for genotypi[INVESTIGATOR_99932].  
 
  
 S1702  
 Page 62  
 Version Date 7/10/[ADDRESS_110191] Pregnancy Report ing Consent  
 
*  NOTES FOR LOCAL INSTITUTION INFORMED CONSENT AUTHORS:  
 
• This template [COMPANY_011] -direct pregnancy reporting consent is provided as a tool to be used 
in the event that the female partner of a male study participant becomes pregnant while the study participant is on study treatment. This consent is not mandatory for  female 
partners of  all male patients, only those who will submit additional pregnancy information 
to [COMPANY_011] . Sites may use local pregnancy reporting consent forms providing that the y 
include adequate information as provided in this document, and pregnancy reporting 
consent is obtained in some written and IRB approved form prior to reporting pregnancy 
information to [COMPANY_011] . Note that patients consent to pregnancy prevention as part  of the 
clinical trial consent, so pregnancy events are not expected during the trial.  
 
• This template has been reviewed by [CONTACT_22688]/NCI and is the official consent document 
for this study. Local IRB changes to this document are allowed. It is suggested that s ections 
of this document that are in bold type be used in their  entirety.  
 
*  These notes for investigators are instructional and should not be included in the informed 
consent form given to the prospective participant.  
 
 
[COMPANY_011]-Direct Pregnancy Reporting Consent for Female Partners of  
Male Study Participants  
 
What is the purpose of this consent form?  
 
You are the partner of a male study participant that took the drug isatuximab as part of 
the study S1702, and you have become pregnant. [COMPANY_011], the drug’s manufacturer, is 
trying to learn more about how the drug affects the developi[INVESTIGATOR_99933]. 
They would like to collect information about you, your pregnancy, the baby’s development during the pregnancy, and the outcome of the pregnancy. This will help them to better inform future patients and the partners of future patients who receive the 
drug about what their pregnancy risks might be. The purpose of this consent form is to ask your permission for the study doctor/nurse to collect this information and provide it 
to [COMPANY_011].  If you accept, your medical information regarding the pregnancy may be shared with people or groups associated with the study. 
 
Procedures  
 Study participants should not fath er a child during the study treatment, or for up to 12 
weeks after the study is over. The participant’s consent form for the treatment study 
discussed this in more detail.  Information on your sex life habits might be collected.  
 If a participant fathers a child during the study treatment or for up to [ADDRESS_110192] one year after the birth.  
 S1702  
 Page 63  
 Version Date 7/10/19  
 
  
 
The information [COMPANY_011] will ask for is as follows: 
 
• What are the first date of your last menstrual period and estimated date of 
conception? 
• When during your pregnancy was the first exposure to the drug? 
• Do you have any other risk factors that would affect the pregnancy (high blood pressure, diabetes, history of abnormal pregnancy, etc.)? 
• Did you smoke, drink alcohol, or use any illegal drugs during the pregnancy? 
• How many previous pregnancies and children have you had, and were there any problems? 
• Outcome of the pregnancy (birth, stillbirth, miscarriage, etc.)?  
• Was the baby [CONTACT_99983]? 
• Is the baby [CONTACT_99984], and what is his/her length, weight and head measurement?  
 
Your personal identifying information will not be provided to [COMPANY_011]. Your partner’s SWOG patient ID will be the only identifying information sent. [COMPANY_011] will not have 
access to the secure study database for S1702 that links SWOG patient IDs to patient 
identifying information.  
 If you consent, the study doctor/nurse will gather this information on a form and send it to [COMPANY_011]. The information will be sent over a secure system. The doctor/nurse may need to ask you questions to get the necessary information. [COMPANY_011] will put your  information 
into a database with the information from others who have provided pregnancy information, and analyze it to see if and how the drug has affected the reported pregnancies. They will need to collect this information throughout your pregnancy  and 
for a year after your baby [CONTACT_50835]  – at the time you initially learn of the pregnancy, at the 
time of any event  during the pregnancy, at the end of the pregnancy , and a year after the 
baby [CONTACT_50835].  
 You will be told about any new information that might change your decision to be in this follow-up.  You may be asked to sign a revised consent form if this occurs.  
If you do not sign this consent, it will not affect your or your partner’s treatment on  the 
S1702 study.  
 By [CONTACT_50841], you are agreeing to allow the information about you, your pregnancy, and your baby’s development during the pregnancy  and up to a 
year after your baby [CONTACT_99985]. 
 
  
 S1702  
 Page 64  
 Version Date 7/10/19  
 
  
 
What possible risks are there?  
 
Since this follow -up is observational only, no physical risk is expected. 
 If you provide this information, you may be asked sensitive or private questions about you and your pregnancy and sexual activity which you normally do no t 
discuss. You may have some emotional discomfort from answering these questions.  
 There is also a possible risk that your personal or medical information or your 
child’s personal or medical information might be compromised. Secure programs 
and procedures are in place to protect your personal information, your personal information is not provided to [COMPANY_011] , and we will do our best to make sure that 
personal information is kept private. However, we cannot guarantee total privacy. There is a chance that some of this personal or medical information may be given 
out as required by [CONTACT_2371]. If any information that is sent to [COMPANY_011] is published or 
presented at scientific meetings,  your name [CONTACT_99991].  
 
What possible benefit s can I expect?  
 This is not a treatment study.  You are not expected to receive any direct medical benefits from this follow -up. 
 The information from this follow-up may lead to a better knowledge and treatment in the future for pregnant women and fetuses who could be exposed to isatuximab.  You will not be paid for your participation in this follow-up. 
 
What are the costs?  
 You will not have any costs for being in this follow-up.    This follow-up will not cover any costs related to your pregnancy, delivery or care of your child.  You and/or your medical/hospi[INVESTIGATOR_99934].  
Can I stop providing information?  
 Your participation in this follow-up is voluntary.  You can decide to stop providing information to [COMPANY_011] at any time. However,  information that has already been sent 
cannot be taken back. If you decide to stop, no further information about you, your pregnancy, or the pregnancy outcome will be sent to Sano fi. 
 
 S1702  
 Page 65  
 Version Date 7/10/19  
 
  
Your decision will not result in any penalty or loss of benefits to which you or your child 
are entitled.  
 Your participation in this follow-up may be stopped at any time by [CONTACT_99986].  
 
Who can ans wer my questions about this?  
 You can talk to the study doctor about any questions or concerns you have about this study or to report side effects or injuries. Contact [CONTACT_39635] __________________ (insert name [CONTACT_99992][s])  at __________________ (insert telephone number).  
 
Signature  
 
I have read this consent form or had it read to me. I have discussed it with the study doctor and my questions have been answered. I will be given a signed copy of this form. I agree to take part in this follow-up. 
  Partner’s signature________________________________ 
 
Date of signature_   
 
 
 
  
  
 S1702  
 Page 66  
 Version Date 7/10/19  
 
  
 
18.5 [COMPANY_011] Exposure During Pregnancy (EDP) Form  
 
Complete whenever an embryo or fetus has been exposed to isatuximab.  
 
Submit via e- mail as soon as pregnancy of female partner of male patient has been 
diagnosed.  
 
E-mail:  [EMAIL_1978]  and derya.cetiner -[EMAIL_1979]  
 
 
 
 
     
 
     
 
  
  
 
     
 
 
  Pregnancy  
 First Date of Late Menstrual Period (DD -MM-YYYY): ________________  
  
 Estimated Date of Conception (DD- MM-YYYY):           ________________  
                                 
 Relevant History  
Risk factors for adverse pregnancy outcomes including environmental or occupational 
exposures, e.g. hypertension, diabetes, etc. Family history of congenital 
abnormality/genetic diseases, consanguinity (or any family relation or lineage) between 
parents (specify degree):  
  
  
1) Did mother smoke during pregnancy?  
☐ No   ☐ Yes: Number per day? _____________  
 
2) Did the mother drink alcohol during the  pregnancy?  
☐ No   ☐ Yes: Frequency? _____________  
 
3) Did the mother use illicit drugs during the pregnancy?  
☐ No   ☐ Yes: Frequency? _____________  
 
 S1702  
 Page 67  
 Version Date 7/10/19  
 
  
 
 
 
     
 
     
 
     
 
    
 
     
 
     
 
    
 
     
 
     Exposure to Products: Maternal  
Were any drugs (e.g., OTC, medical prescription) taken by [CONTACT_99987]?  
 
☐No  
 ☐Yes, please specify  (for each drug):                                                                       
 
Drug Name : 
[CONTACT_99993] : 
Start Date:  
Stop Date:  
Reason for Stoppi[INVESTIGATOR_007]:  
Dose:  
Formulation:  
Frequency:  
 Drug Name : 
[CONTACT_99993] : 
Start Date:  
Stop Date:  
Reason for Stoppi[INVESTIGATOR_007]:  
Dose:  
Formulation:  
Frequency:  
 
Drug Name : 
[CONTACT_99993] : 
Start Date:  
Stop Date:  
Reason for Stoppi[INVESTIGATOR_007]:  
Dose:  
Formulation:  
Frequency:  
 
Drug Name : 
[CONTACT_99993] : 
Start Date:  
Stop Date:  
Reason for Stoppi[INVESTIGATOR_007]:  
Dose:  
Formulation:  
Frequency:  
 
(Include Product Indication; Start Date \ Stop Date; Reason for stoppi[INVESTIGATOR_007]; Dose; 
Formulation and Frequency for each drug taken)  Obstetrical History 
Number of previous pregnancies/children. Outcome of previous pregnancies (live birth, 
miscarriage, elective termination, late fetal death, ectopic pregnancy, molar pregnancy).  
Previous maternal pregnancy complications. Previous fetal/neonatal abnormalities and 
type. History of sub-fertility.:  
  
 
 
 S1702  
 Page 68  
 Version Date 7/10/19  
 
  
 
 
 
 
 
 
     
 
    
 
    Outcome of Pregnancy            Date of outcome (DD -MM-YYYY):  ___________  
Check one  
☐Full term live birth  ☐Preterm live birth  ☐Stillbirth  
☐Spontaneous abortion/miscarriage  ☐Induced abortion  ☐Unknown 
 
Gestational age at birth in weeks, (if known):  _____________  
 
Infant  
Check one  
☐Normal  ☐Congenital Malformation/Anomaly**   
☐Other neonatal problem** ☐Unknown 
☐Other neonatal problem/abnormality (include dysmaturity, neonatal illness, 
hospi[INVESTIGATOR_059], drug therapi[INVESTIGATOR_014]) Specify:   _____________   
 
Apgar Score:  1min  _____________ 5min  _____________  
 
☐Male   ☐ Female  
 
Birthweight   _____________ grams  
Or, if birthweight in grams unknown: Birthweight ☐ lb  ☐oz 
 
Length at birth: in cm Head Circumference at birth:  _____________☐  in  ☐cm  
 
**Complete also the Serious Adverse Event section of the report, specifying the 
diagnosis as the Serious Advers e Event  
 S1702  
 Page 69  
 Version Date 7/10/[ADDRESS_110193] Name:  _________________________ First Name :  
______________________________  
Subject/Patient Date of Birth:  I_  ._ I_ ._ I_ ._ ._ ._  I  
I am being treated with ISATUXIMAB , which may interfere with type and screen test results . 
Since:  I_  ._  I_  ._  I_  ._  ._  ._   I  (MM/DD /YYYY)   Until :  I_  ._  I_  ._  I_  ._  ._  ._   I (MM/DD /YYYY)  
 
 
The blood bank should be aware that you are receiving an anti -CD38 treatment (isatuximab) 
before any red blood cells transfusion : 
 
Before starting isatuximab my  blood test results collected o n    /   /      were (MM/DD/YYYY)  
 
        Blood type:  _______________________________________________________________ 
        Indirect Coombs test (antibody screen):  _______________________________________  
 Contact [CONTACT_99988]:  ___________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
 Note to Transfusion Services: Treatment with anti- CD38 antibodies can result in interference with  
blood bank serologic tests. Please review the bulletin from  the American Association of Blood  
Banks for more information on this potential interference  
(http://www.aabb.org/programs/publications/bulletins/Documents/ab16-
02.pdf#search=anti%3DCD38).  
 
 
  
 S1702  
 Page 70  
 Version Date 7/10/19  
 
  
18.7 Measuring Orthostatic Blood Pressure  
 
Instructions : 
 
1. Have the patient lie down for [ADDRESS_110194] the patient stand for 1- 2 minutes (stand by [CONTACT_99989]).  
 6. Measure and record blood pressure and pulse rate.  
 
A drop in blood pressure of > 20 mm Hg, or in diastolic blood pressure of >10 mm Hg, or experiencing lightheadedness or dizziness is considered abnormal.  
 
Note:  The remainder of this form is provided as a tool and may be used and maintained in 
the patient chart; however, sites are not required to use or maintain this form.  
 
Recording Measurements  
 
Patient  ID:   Date:    Time:  
 
You do not need an 
order for measuring Orthostatic Blood 
Pressure. Position   Time  Blood Pressure and 
Heart Rate  Associated 
Symptoms  
 
Lying down  
   
 
 
 5 minutes  BP______/_____  
HR____________  
BP ______/______    
 
Sitting  
 
  
  
 1-2 minutes  HR___________  
BP______/______  
HR_____________   
 
Standing  
  
 
 
 1-2 minutes  HR___________  
BP______/______  
HR_____________   
 
Symptoms of Orthostatic Hypotension  Patients Most at Risk  
Dizziness, feeling faint  Older patients (approx. 20% of people > 65)  
Light headedness  HI Bleed/Anemic  
Blurred vision  Dehydration  
Disorientation and confusion  Surgical patients  
Weakness/fatigue/falling  Diabetics  
Chest pain  Heart disease  
Expectation:  Perform Orthostatic BP on all high -risk patients at least once per shift.  
 
Adapted from Tip Sheet available at  
http://www.hret-hiin.org/Resources/falls/16/measuring_orthostatic_blood_pressure_tip_sheet_3.7.16.pdf . 
 
